risedronic acid profile

Risedronic acid is a bisphosphonate medication used to treat and prevent osteoporosis, Paget's disease of bone, and hypercalcemia. It is also used to treat bone metastases from cancers such as breast cancer, prostate cancer, and multiple myeloma. Risedronic acid works by inhibiting the activity of osteoclasts, which are cells that break down bone. This results in increased bone density and a reduced risk of fractures. Risedronic acid is synthesized through a multi-step process involving the reaction of a phosphorus-containing compound with a diphosphonic acid. It is typically administered orally, but it can also be given intravenously. Risedronic acid is a potent inhibitor of bone resorption and has been shown to be effective in reducing fracture risk in patients with osteoporosis. It is also effective in treating Paget's disease of bone and hypercalcemia. However, risedronic acid can cause side effects such as gastrointestinal upset, esophagitis, and osteonecrosis of the jaw. It is important to note that risedronic acid should be taken on an empty stomach and with a full glass of water. Patients should also avoid lying down for at least 30 minutes after taking risedronic acid.'

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5245
CHEMBL ID	923
CHEBI ID	8869
SCHEMBL ID	18378
MeSH ID	M000603388

Synonym
AC-1295
BIDD:GT0010
AB01275490-01
gtpl3176
ne-58095
[1-hydroxy-1-phosphono-2-(3-pyridyl)ethyl]phosphonic acid
phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-
(1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid)
risedronate ,
risedronic acid
C08233
105462-24-6
DB00884
acide risedronique [inn-french]
(1-hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid
ne 58019
acidum risedronicum [inn-latin]
risedronic acid [inn:ban]
acido risedronico [inn-spanish]
hsdb 7326
1-hydroxy-2-(3-pyridinyl)ethylidene bis-phosphonic acid
RIS ,
bisphosphonate 1
risdronate
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid
bdbm12576
jmc515594 compound 64
chembl923 ,
(1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
HMS2090C21
ridron
m05ba07
chebi:8869 ,
risedronic acid (inn)
ridron (tn)
D08484
(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid
A801245
1-hydroxy-2-(3-pyridinyl)ethylidenebisphosphonicacidmonohydrate;risedronic acid monohydrate
unii-km2z91756z
km2z91756z ,
acido risedronico
acidum risedronicum
acide risedronique
FT-0642593
risedronic acid [hsdb]
2-(3-pyridinyl)-1-hydroxyethane diphosphonic acid
risedronic acid [inn]
risedronic acid [mi]
risedronic acid [who-dd]
risedronic acid [mart.]
risedronate [vandf]
S1874
AKOS015892564
CS-1964
HY-B0148
SCHEMBL18378
IIDJRNMFWXDHID-UHFFFAOYSA-N
2-(3-pyridyl)-1-hydroxyethane-1,1-bisphosphonic acid
AB01275490_02
DTXSID2023563 ,
phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-
sr-05000001495
(1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)bis(phosphonic acid)
SR-05000001495-1
NCGC00386377-01
Q408724
risedronic acid (actonel)
mfcd00867080
1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyldiphosphonic acid
AS-13584
BCP13805
AMY3524
(1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid
HMS3741A17
EN300-117266
phosphonic acid, p,p'-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis-
Z1501485357
acide risedronique (inn-french)
risedronsaure
acidum risedronicum (inn-latin)
acido risedronico (inn-spanish)
acide risedroniqe
dtxcid303563
risedronic acid (mart.)

Excerpt	Reference	Relevance
" Risedronate was well tolerated, had a good safety profile, and was not associated with gastrointestinal adverse events."	( Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. Adami, S; Devogelaer, JP; Eusebio, RA; Hughes, RA; Laan, RF; Reid, DM; Sacco-Gibson, NA; Wenderoth, DH, 2000)	0.31
" Some bisphosphonates have been associated with upper gastrointestinal (GI) tract adverse effects."	( Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Adami, S; Bolognese, MA; Ernst, TF; Ettinger, MP; Josse, RG; Lindsay, R; Mulder, H; Roberts, A; Stevens, KP; Taggart, H; Zippel, H, 2002)	0.31
" The risk of an adverse upper GI event increases when these drugs are used concurrently with nonsteroidal anti-inflammatory drug (NSAID) therapy, but this incidence is no more than that observed with concurrent placebo and NSAID therapy."	( Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Baker, DE, 2002)	0.31
"To evaluate the frequency of upper gastrointestinal (GI) tract adverse events associated with risedronate during two (2-year) randomized, double-blind, parallel-group, placebo-controlled studies."	( Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005)	0.33
" The number of upper GI tract adverse events was similar between treatment groups, with no dose-related response: 161 for placebo, 176 for rlsedronate at 5 mg/d, and 150 for risedronate at 15 mg/d."	( Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005)	0.33
"The results of this study show that risedronate regimens at 5 mg/d or 15 mg/d as well as once weekly at 35 mg or 50 mg are not associated with an increased frequency of upper GI tract adverse events, even in patients who have an increased risk for such events."	( Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K, 2005)	0.33
" Risedronate was safe and effective in osteoporotic women with mild, moderate, or severe age-related renal impairment."	( Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005)	0.33
" Risedronate is a pyridinyl bisphosphonate well established as safe and effective in the treatment and prevention of osteoporosis."	( Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005)	0.33
" The incidences of overall adverse events and of renal function-related adverse events were similar in the placebo and risedronate 5 mg groups regardless of renal function."	( Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005)	0.33
"These findings show that risedronate is safe and effective in osteoporotic women with age-related mild, moderate, or severe renal impairment."	( Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005)	0.33
" The changes were compared in bone mineral density (BMD), bone metabolism markers and adverse events after 12 months oral administration of risedronate sodium."	( Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis. Chen, L; Deng, X; Li, Y; Zhang, Z, 2005)	0.33
"Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens."	( Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006)	0.33
" RCTs have demonstrated that the incidence of gastrointestinal tract adverse events in postmenopausal osteoporotic women treated with bisphosphonates and placebo are similar, and also the long-term efficacy and safety of alendronate and risedronate."	( Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto, J; Sato, Y; Takeda, T, 2006)	0.33
"To examine in a major cohort of patients whether or not musculoskeletal adverse effects (MAEs), similar to those seen in intravenous bisphosphonates (BP), might occur also in high dosage oral treatment regimens with alendronate (ALN) and risedronate (RSN)."	( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM, )	0.13
" Risedronate administration in the dose which is considered to be comparable to a dose of risedronate used for treatment of osteoporosis in women seems to be safe in terms of effects on mouse haematopoiesis."	( Risedronate has no adverse effects on mouse haematopoiesis. Broulík, P; Necas, E; Pelichovská, T; Sefc, L, 2007)	0.34
" The review specifically considers upper gastrointestinal (UGI) adverse events (AEs), renal toxicity, influenza-like illness, osteonecrosis of the jaw and evidence on how to treat or prevent these events."	( Safety considerations with bisphosphonates for the treatment of osteoporosis. Civitelli, R; Emkey, R; Strampel, W, 2007)	0.34
" The aim of this study was to compare the adverse effects (AEs) of alendronate, etidronate and risedronate prescribed in a non-selected population, attending a single institution on an outpatient basis."	( Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases. Anastasilakis, AD; Avramidis, A; Goulis, DG; Kita, M, )	0.13
" Bone mineral density, bone turnover markers, fractures, and adverse events were evaluated."	( Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008)	0.35
" The incidence of adverse events, adverse events leading to withdrawal, and upper gastrointestinal tract adverse events were similar in the 2 treatment groups."	( Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008)	0.35
" In placebo controlled trials it has been shown to be safe and effective in preventing fractures."	( Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Adachi, JD; Bobba, R, 2007)	0.34
" Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule."	( Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J, 2008)	0.35
" Although these agents are generally well tolerated, serious gastrointestinal adverse events, including hospitalization for gastrointestinal bleed, may arise."	( Comparative gastrointestinal safety of weekly oral bisphosphonates. Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T, 2009)	0.35
"The objective of this study was to compare the changes on bone mineral density, and the effects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax®) or branded risedronate (Actonel®) once weekly."	( Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Möller, G; Ringe, JD, 2009)	0.35
" Bone mineral density (BMD), bone turnover markers (BTMs), fractures, and adverse events were evaluated."	( Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Balske, A; Benhamou, CL; Bolognese, MA; Brown, JP; Burgio, DE; McClung, MR; McCullough, LK; Miller, PD; Recker, RR; Sarley, J; Zanchetta, J, 2012)	0.38
" The incidence of adverse events leading to withdrawal and serious adverse events were similar across treatment groups."	( Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Balske, A; Benhamou, CL; Bolognese, MA; Brown, JP; Burgio, DE; McClung, MR; McCullough, LK; Miller, PD; Recker, RR; Sarley, J; Zanchetta, J, 2012)	0.38
" However, there seems to be a limited awareness that oral bisphosphonates can also induce adverse effects in the soft tissues of the oral cavity, as indicated by the paucity of reported cases in the literature."	( Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. Kharazmi, M; Persson, U; Warfvinge, G, 2012)	0.38
"The database of the Medical Products Agency-Sweden was searched for adverse effects from oral bisphosphonates manifesting in the oral and maxillofacial region."	( Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. Kharazmi, M; Persson, U; Warfvinge, G, 2012)	0.38
"A total of 83 cases of adverse reactions to oral bisphosphonates were retrieved from the search."	( Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. Kharazmi, M; Persson, U; Warfvinge, G, 2012)	0.38
" These adverse drug reactions are not limited to alendronate and may also be induced by etidronate and risedronate."	( Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity. Kharazmi, M; Persson, U; Warfvinge, G, 2012)	0.38
" The safety of risedronate was evaluated based on adverse events, laboratory data, vital signs, and physical examination results."	( Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Boonen, S; Eusebio, R; Lorenc, RS; Orwoll, ES; Stoner, KJ; Wenderoth, D, 2012)	0.38
" Bone mineral density (BMD), bone turnover markers, new vertebral fractures, and adverse events were evaluated."	( Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013)	0.39
" The incidence of adverse events, adverse events leading to withdrawal, and upper gastrointestinal tract adverse events were similar in the two treatment groups."	( Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013)	0.39
" An investigation of the cytotoxicity of the RA-CSC systems upon osteoblast-like cells showed no toxic effects of concentrations up to 2%."	( Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium silicate cement as a risedronate delivery system. Gong, T; Häfeli, UO; Sun, C; Troczynski, T; Wang, Z; Yang, Q; Zhang, Y, 2014)	0.4
" Overall and serious adverse events were similar between groups."	( Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Brown, JP; Fahrleitner-Pammer, A; Ferreira, I; Hawkins, F; Ho, PR; Hofbauer, LC; Micaelo, M; Minisola, S; Papaioannou, N; Roux, C; Siddhanti, S; Stone, M; Wagman, RB; Wark, JD; Zillikens, MC, 2014)	0.4
" Bone mineral density (BMD), biochemical markers of bone metabolism, fractures, and adverse events (AEs) were evaluated."	( Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen. Hagino, H; Horii, S; Kishimoto, H; Nakamura, T; Ohishi, H, 2014)	0.4
" The subjects' bone mineral densities (BMDs), bone turnover markers (P1NP and β-CTX), new vertebral fractures, and adverse events were assessed at baseline and during the treatments."	( The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Chen, DC; Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Jin, XL; Lin, H; Liu, YJ; Tang, H; Wang, C; Wang, L; Xia, WB; Yue, H; Zhang, H; Zhang, ZL, 2015)	0.42
" The incidences of clinical adverse events were 48."	( The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Chen, DC; Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Jin, XL; Lin, H; Liu, YJ; Tang, H; Wang, C; Wang, L; Xia, WB; Yue, H; Zhang, H; Zhang, ZL, 2015)	0.42
" A random-effects model within a Bayesian framework was applied to compare treatment effects as standardized mean difference (SMD) with their corresponding 95% credible interval (CrI), while odds ratio (OR) was applied to compare adverse events with 95% CrI."	( Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y, 2017)	0.46
" For safety assessment, the incidence of adverse events (AEs) demonstrated no statistical difference between agents and placebo."	( Efficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis. Chen, H; Ma, H; Ma, J; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y, 2017)	0.46
" The groups had not only comparable Model for End-stage Liver Disease score and esophageal varices degree, but also similar incidence of digestive adverse effects."	( Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial. Caramori, CA; Lima, TB; Nunes, HRC; Qi, X; Romeiro, FG; Santos, LAA; Silva, GF, 2019)	0.51
" They are associated with gastrointestinal adverse reactions the most severe being an esophageal ulcer."	( Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients. Bouin, M; Nguyen, PV; Ste-Marie, LG, 2021)	0.62
"The incidence of adverse reaction was similar to that reported in community trials."	( Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients. Bouin, M; Nguyen, PV; Ste-Marie, LG, 2021)	0.62
" Incident of non-traumatic spine fractures and adverse events were tracked as safety endpoints."	( Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial. Amasaki, Y; Atsumi, T; Fujieda, Y; Fukaya, S; Furukawa, S; Furusaki, A; Horita, T; Iwasaki, N; Kasahara, H; Katayama, K; Kato, M; Katsumata, K; Kurita, T; Matsui, K; Nishimoto, N; Oku, K; Sagawa, A; Shane, P; Takahata, M; Takeda, T; Takeuchi, K; Tanimura, K; Tsutsumi, A; Yasuda, S, 2021)	0.62
"Atypical femur fracture (AFF) is a rare but catastrophic adverse event first reported in the long-term use of alendronate, one of the most commonly used drugs for osteoporosis currently."	( Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. Chen, Y; Huang, Y; Xiao, Y, 2023)	0.91

Excerpt	Reference	Relevance
" Pharmacokinetic parameters were estimated by simultaneous analysis of risedronate serum concentration and urinary excretion rate-time data."	( The effect of dosing regimen on the pharmacokinetics of risedronate. Clay, ME; Heise, MA; Melson, CW; Mitchell, DY; Nesbitt, JD; Pallone, KA; Russell, DA, 1999)	0.3
" Mean Cmax (0."	( Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. Brezovic, CP; Eusebio, RA; Kelly, SC; Mitchell, DY; Nesbitt, JD; Pallone, KA; Powell, JH; Sacco-Gibson, NA; Thompson, GA, 2000)	0.31
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Pharmacodynamic study was performed on Dexamethasone (DEX) induced osteoporotic model."	( Design and Development of Bioceramic Based Functionalized PLGA Nanoparticles of Risedronate for Bone Targeting: In-vitro Characterization and Pharmacodynamic Evaluation. Ahmad, FJ; Gupta, S; Kalam, A; Manglani, K; Rawat, P; Talegaonkar, S; Vohora, D, 2015)	0.42
" Biochemical and in-vivo pharmacokinetic studies on osteoporotic rat model treated with different formulations were performed."	( Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment. Ahmad, FJ; Ahmad, I; Gupta, S; Pandey, S; Rawat, P; Talegaonkar, S; Thomas, SC; Vohora, D, 2016)	0.43
"To develop a population pharmacokinetic model that describes the absorption and low plasma levels of risedronate in the body."	( Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Cardozo, B; Karalis, V; Karatza, E, 2021)	0.62

Excerpt	Reference	Relevance
"Therapies utilizing intermittent human parathyroid hormone(1-34) (hPTH[1-34]) in combination with other agents have recently been proposed as possible anabolic regimens for the treatment of osteoporosis."	( Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. Boyce, RW; Eriksen, EF; Franks, AF; Jankowsky, ML; Paddock, CL, 1996)	0.29
" The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat."	( Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. Hunziker, J; Miller, SC; Wronski, TJ, 2000)	0.31
"The relationship between bone turnover and bone tissue and material properties was examined in ovariectomized (OVX) rats treated with risedronate in combination with or without vitamin K2."	( Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2. Ikeda, S; Ito, M; Nakamura, T; Otomo, H; Phipps, RJ; Sakai, A; Tanaka, S, 2004)	0.32
"To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)."	( Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008)	0.35
"Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL."	( Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008)	0.35
" The anti-tumor activities of risedronate in combination with carboplatin, doxorubicin, vincristine or etoposide were assayed with CalcuSyn (Biosoft)."	( Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Kawasoe, Y; Komiya, S; Minami, S; Murayama, T; Ueno, Y; Yamashita, Y; Yokouchi, M, )	0.13
" These results suggested that ECT in combination with risedronate was more effective than risedronate alone for reducing back pain in postmenopausal women with osteoporosis."	( Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis. Iwamoto, J; Takakuwa, M, 2012)	0.38
" A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively)."	( The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. Itoh, S; Sekino, Y; Shinomiya, K; Takeda, S, 2013)	0.39
" We aimed to evaluate the effects of risedronate alone or combined with vitamin K2 on serum ucOC, OC, and incidence of vertebral fractures in elderly osteoporotic patients."	( Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. Aizawa, T; Chida, S; Ebina, T; Hongo, M; Ishikawa, Y; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Saito, H; Shimada, Y, 2014)	0.4
" In the present study, to increase oral BA of the bisphosphonate, a novel enteric-coated tablet (ECT) dosage form of RS in combination with phytic acid (IP6), a natural chelating agent recognized as safe, was formulated."	( Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. Jang, SW; Kang, MJ; Kim, BM; Kim, JS; Son, M, 2016)	0.43

Excerpt	Reference	Relevance
" Although newer bisphosphonates are more potent, oral bioavailability remains < 1%."	( Oral bisphosphonates: A review of clinical use in patients with bone metastases. Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)	0.31
" Low oral bioavailability is the most likely reason for this difference."	( Oral bisphosphonates: A review of clinical use in patients with bone metastases. Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)	0.31
"Food-drug interactions may reduce the bioavailability of drugs taken after meals (negative food effect)."	( Effect of administration site in the gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal. Kamaguchi, R; Kataoka, M; Kokubo, H; Kozaki, T; Masaoka, Y; Sakuma, S; Tanno, FK; Yamashita, S, 2007)	0.34
" However, copies of alendronic acid tablets are approved based on the results of single-dose bioavailability studies in healthy subjects and this is not adequate to establish similar disintegration characteristics."	( In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Crail, DJ; Dansereau, RJ; Perkins, AC, 2008)	0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
"Adducts based on a bisphosphonate drug (sodium risedronate) and titanium dioxide (TiO(2)) particles have been developed and characterized in order to improve the bioavailability of orally administrated bisphosphonates."	( Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates. Beggiato, S; Bignozzi, CA; Bozzi, P; Dalpiaz, A; Dissette, V; Ferraro, L; Leo, E; Pasti, L; Vighi, E, 2010)	0.36
"This study was designed to develop a sensitive and rapid method for the quantitation of risedronate in human urine using ultra-performance liquid chromatography with ultra-violet detector (UPLC-UV) and to compare bioavailability parameter of 5, 35 and 150 mg risedronate."	( UPLC-UV method for determination of risedronate in human urine. Chung, YH; Jeong, JH; Lim, CH; Seo, YH, 2014)	0.4
"The present study was performed to compare the bioavailability of 2 risedronate sodium 35 mg film-coated tablet formulations (test formulation and reference formulation)."	( Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers. Handayani, LR; Rosa, TA; Setiawati, A; Setiawati, E; Sholeh, AB; Simanjuntak, R; Utami, BS; Yunaidi, DA, 2014)	0.4
" However, its oral efficacy is restricted due to its low bioavailability and severe gastrointestinal adverse effects."	( Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats. Byun, Y; Park, JW, 2014)	0.4
" Taken together, the results of this study suggest that chitosan-coated liposomes containing risedronate should be effective for improving the bioavailability of risedronate."	( Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization. Han, HK; Jung, IW, 2014)	0.4
" The results illustrated the potential use of SMEDDS for delivery of poorly absorbed RSD."	( Comparative permeability studies with radioactive and nonradioactive risedronate sodium from self-microemulsifying drug delivery system and solution. Asikoglu, M; Ekinci, M; Gundogdu, E; Ilem-Ozdemir, D; Ozgenc, E, 2015)	0.42
" The low oral bioavailability and known dosing limitations due to food interactions of bisphosphonates have led to development of an oral delayed-release dose form of risedronate 35 mg to be taken weekly, before or after breakfast."	( Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG, 2015)	0.42
"One approach for the enhancement of oral drug bioavailability is the technique of nanoparticle preparation."	( Preparation of risedronate nanoparticles by solvent evaporation technique. Dedkova, K; Devinsky, F; Jampilek, J; Peikertova, P; Pisarcik, M; Placha, D; Vaculikova, E, 2014)	0.4
"The oral bioavailability (BA) of risedronate sodium (RS), an antiresorptive agent, is less than 1% due to its low membrane permeability as well as the formation of non-absorbable complexes with multivalent cations such as calcium ion (Ca(2+)) in the gastrointestinal tract."	( Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. Jang, SW; Kang, MJ; Kim, BM; Kim, JS; Son, M, 2016)	0.43
" Drug package inserts for bisphosphonate supplements indicate that their bioavailability is reduced by high levels of metal cations (Ca(2+), Mg(2+), etc."	( Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. Akagi, Y; Aoyama, T; Itoh, A; Shimomura, H, 2016)	0.43
" Pharmacokinetic studies revealed 6-fold and 4-fold increase in the relative bioavailability after intravenous and oral administration of nanoparticles respectively as compared to marketed formulation confirming better effective drug transport."	( Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: Pharmacokinetic and biochemical assessment. Ahmad, FJ; Ahmad, I; Gupta, S; Pandey, S; Rawat, P; Talegaonkar, S; Thomas, SC; Vohora, D, 2016)	0.43
" The oral bioavailability of risedronate in rats was determined through its percentage excreted in urine after administration of complexed or free risedronate in fed and fasted conditions."	( Reduced food interaction and enhanced gastrointestinal tolerability of a new system based on risedronate complexed with Eudragit E100: Mechanistic approaches from in vitro and in vivo studies. Guzman, ML; Laino, C; Manzo, RH; Olivera, ME; Soria, EA, 2016)	0.43
"In this study, sustained release superabsorbent copolymer particles have been prepared and analyzed to increase bioavailability of orally administered risedronate sodium."	( RELATIVE BIOAVAILABILITY OF RISEDRONATE SODIUM ADMINISTERED IN SUPERABSORBENT COPOLYMER PARTICLES VERSUS ORAL SOLUTION TO NORMAL HEALTHY RABBITS. Abbas, N; Bukhari, NI; Hussain, T; Karim, S; Shahzad, MK, 2016)	0.43
"Risedronate sodium is a bisphosphonate derivative having very low bioavailability when administered through the oral route."	( Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film. Anbu, J; Azamthulla, M; Banala, VT; Mukherjee, D; Ramachandra, SG; Srinivasan, B, 2018)	0.48
"Albeit its well known potency as a postmenopausal osteoporosis treatment, Risedronate suffers from poor oral bioavailability and high oral toxicity."	( Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. Abdallah, OY; Elnaggar, YSR; Hazzah, HA; Omran, S, 2019)	0.51
"Delivery of bisphosphonates-like risedronate has been a major challenge till date due to its poor bioavailability and gastrointestinal tract adverse effects."	( Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies. Anbu, J; Mukherjee, D; Murahari, M; Santhosh, S; Teja, BV, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"Risedronate sodium (RS) is a potent inhibitor of bone resorption, having an extreme poor permeability and limited oral bioavailability (0."	( QbD Approach for Novel Crosslinker-Free Ionotropic Gelation of Risedronate Sodium-Chitosan Nebulizable Microspheres: Optimization and Characterization. El-Laithy, HM; Elkady, OA; Tadros, MI, 2019)	0.51
" To avoid the undesirable adverse effects of long-term usage of bisphosphonates and improve their bioavailability in the bone microenvironment, we initially encapsulated risedronate (RIS) molecules inside nanoscale zeolitic imidazolate framework-8 particles (nZIF-8) by a one-step synthesis method to generate RIS@ZIF-8 nanoparticles."	( Zeolitic Imidazolate Framework-8 Encapsulating Risedronate Synergistically Enhances Osteogenic and Antiresorptive Properties for Bone Regeneration. Cheng, X; Gao, X; Liu, Y; Pei, X; Wan, Q; Wang, J; Xue, Y; Zhu, Z, 2020)	0.56
" It is a BCS class III drug having poor oral bioavailability (<0."	( Investigation on Potential of Chitosan Nanoparticles for Oral Bioavailability Enhancement of Risedronate Sodium. Desai, J; Suthar, N; Thakkar, HP, 2021)	0.62
"High lung deposition and bioavailability of RIS was monitored with 88."	( Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling. Cao, J; Chen, H; Chen, R; Liu, D; Su, B; Tang, Y; Wu, D; Xu, J; Xu, W, 2022)	0.72

Excerpt	Relevance	Reference
" Rats were dosed concomitantly with indomethacin (40 mg/kg, subcutaneously) and an amino or pyridinyl bisphosphonate (orally at."	( Nonclinical model for assessing gastric effects of bisphosphonates. Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN, 1997)	0.3
" In these studies another formulation of the drug and other dosing instructions are used."	( A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Christiansen, C; Clemmesen, B; Ravn, P; Reginster, JY; Taquet, AN; Zegels, B, 1997)	0.3
" Serum and urine samples were obtained for 48 hours after dosing for risedronate analysis."	( Risedronate gastrointestinal absorption is independent of site and rate of administration. Bekker, PJ; Clay, ME; Dunlap, LE; Eusebio, RA; Mitchell, DY; Nesbitt, JD; Pallone, KA; Russell, DA, 1998)	0.3
" Risedronate was well tolerated during the dosing phase of the study as evidenced by clinical observations, body weight gain and food consumption which were not significantly different from the vehicle controls."	( Evaluation of the effects of risedronate on hepatic microsomal drug metabolizing enzyme activities following administration to rats for 14 days: lack of an induction response. Hu, JK; Schwecke, WP; Smith, BJ, 1998)	0.3
" The data show that there is a dose-response with risedronate: patients who received 30 mg oral risedronate for 28 days benefited most, with a mean percentage decrease in AP excess of 72."	( Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. Bekker, PJ; Brown, JP; Hosking, DJ; Johnson, TD; Johnston, CC; Reginster, J; Ryan, WG; Ste-Marie, L, 1999)	0.3
"5-1 h before breakfast or 2 h after an evening meal support previous clinical studies where risedronate was found to have similar effectiveness using these dosing regimens."	( The effect of dosing regimen on the pharmacokinetics of risedronate. Clay, ME; Heise, MA; Melson, CW; Mitchell, DY; Nesbitt, JD; Pallone, KA; Russell, DA, 1999)	0.3
" Oral dosing should not be substituted for intravenous administration in the treatment of malignant osteolysis."	( Oral bisphosphonates: A review of clinical use in patients with bone metastases. Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)	0.31
" Serum samples were obtained for 72 h after dosing, and urine samples were collected for 72 h after dosing and then periodically for 6 weeks."	( Effect of renal function on risedronate pharmacokinetics after a single oral dose. Eusebio, RA; Kelly, SC; Mitchell, DY; Nesbitt, JD; Pallone, KA; Powell, JH; Russell, DA; St Peter, JV; Thompson, GA, 2000)	0.31
" The study was designed as a dose-response study, and the site-specific effects of immobilization and of treatment are described."	( Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS, 2000)	0.31
" The present study compared the potential for alendronate and risedronate to produce endoscopic upper GI mucosal irritation using the highest approved dosage regimens for the two agents."	( An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Graham, DY; Lanza, F; Malaty, HM; Musliner, T; Quan, H; Reyes, R; Sahba, B; Schwartz, H, 2000)	0.31
" The oesophageal transit is rapid and given the rapid disintegration and gastric emptying, oesophageal contact occurring via reflux of risedronate was unlikely since most, if not all, of the dosage form exited from the stomach within 30 min."	( Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects. Blackshaw, PE; Dansereau, RJ; Frier, M; Hathaway, S; Juan, D; Li, Z; Long, P; Perkins, AC; Spiller, RC; Wilson, CG, 2001)	0.31
" The time course of changes in PTH levels following cessation of dosing was unaffected by calcium supplementation."	( Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. Collette, J; Eastell, R; Ethgen, D; Reginster, JY; Roumagnac, I; Russell, RG; Zegels, B, 2001)	0.31
" As a result of this concern, dosage forms are now being designed to exhibit minimal esophageal adhesion."	( The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans. Crail, D; Dansereau, R; Lane, M; McCargar, L; Myers, W, 2001)	0.31
"As our population ages, and the consumption of pharmaceutical products rises, the incidence of solid oral dosage forms lodging in the esophagus is likely to increase and may be formulation dependent."	( The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water. Blackshaw, PE; Dansereau, RJ; Frier, M; Hathaway, S; Li, Z; Perkins, AC; Spiller, RC; Vincent, RM; Wenderoth, D; Wilson, CG, 2001)	0.31
" Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form."	( Role of alendronate and risedronate in preventing and treating osteoporosis. Leonard, M; Licata, AA; Peters, ML, 2001)	0.31
" We found, in dose-response studies, that alendronate and risedronate inhibit bone resorption (in pit assays) at doses tenfold lower than those reducing osteoclast number."	( Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Halasy-Nagy, JM; Reszka, AA; Rodan, GA, 2001)	0.31
" Also, the risk of these adverse GI tract events can be decreased by following the dosing instructions (e."	( Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Baker, DE, 2002)	0.31
" A 70-mg once-weekly dosage form of alendronate has recently been approved and clinical experience with its gastrointestinal tolerability is ongoing."	( What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Graham, DY, 2002)	0.31
" This dosage was well tolerated with a low incidence of GI side effects."	( Bone density changes with once weekly risedronate in postmenopausal women. Delaney, MF; Hurwitz, S; LeBoff, MS; Shaw, J, 2003)	0.32
"The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice."	( Tolerability and compliance with risedronate in clinical practice. Hamilton, B; McCoy, K; Taggart, H, 2003)	0.32
" To assess the anti-fracture efficacy of this new regimen, we have analyzed the fracture data collected in an active controlled study of risedronate dosing regimens (the Once-a-Week study) using matched historical control data from previous placebo-controlled trials."	( Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Brown, J; Kasibhatla, C; Li, Z; Lindsay, R; Watts, NB, 2003)	0.32
" The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate."	( Bisphosphonates: new indications and methods of administration. Reid, IR, 2003)	0.32
"To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis."	( Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L, 2003)	0.32
" Therefore, the pharmacokinetic profile of risedronate was considered to show linearity in a dosage range of up to 20 mg."	( Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. Cyong, JC; Gonsho, A; Ogura, Y; Orimo, H, 2004)	0.32
"The efficacy and tolerability of risedronate once-a-week dosing (35 and 50mg) were compared with risedronate daily dosing (5mg) in a 2-year study in women with osteoporosis."	( Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB, 2004)	0.32
" Risedronate 35 mg once a week is considered the optimal dose want a once-a-week dosing regimen."	( Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB, 2004)	0.32
" We conclude that prophylactic treatment with risedronate in a training population at high risk for stress fracture using a maintenance dosage for the treatment of osteoporosis does not lower stress fracture risk."	( The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Burr, D; Finestone, A; Goldich, Y; Kaufman, S; Kreiss, Y; Liebergall, M; Milgrom, C; Novack, V; Pereg, D; Zimlichman, E, 2004)	0.32
"The objective of this review is to present the clinical profiles of the once-weekly and once-daily dosing formulations of alendronate and risedronate, the 2 bisphosphonates currently available in the United States for the prevention and treatment of postmenopausal osteoporosis."	( Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Emkey, R, 2004)	0.32
"To evaluate pharmacists' knowledge of approved dosing information for cyclic etidronate, alendronate and risedronate in the treatment of postmenopausal osteoporosis; and to assess its relationship to demographic and pharmaceutical care factors."	( Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information. Kendler, DL; Li, WW, 2004)	0.32
"Fax-back questionnaire to evaluate pharmacists' knowledge of approved bisphosphonate dosing information and their involvement in pharmaceutical/patient care activities through independent indices."	( Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information. Kendler, DL; Li, WW, 2004)	0.32
"Mean bisphosphonate dosing knowledge score was 76 +/- 11% (mean +/- SD)."	( Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information. Kendler, DL; Li, WW, 2004)	0.32
"There is a wide range of knowledge of bisphosphonate dosing and delivery of pharmaceutical care amongst community pharmacists surveyed."	( Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information. Kendler, DL; Li, WW, 2004)	0.32
" Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis."	( Oral antiresorptive therapy. Hosking, DJ; Pande, I, 2005)	0.33
" Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis."	( Oral antiresorptive therapy. Hosking, DJ; Pande, I, 2004)	0.32
" Reducing oral bisphosphonate dosing frequency is one measure available to increase therapy convenience and practicality, with the hope of improving compliance and persistence."	( Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A, 2005)	0.33
" However, compliance and persistence rates for both regimens were suboptimal, suggesting that less frequent dosing intervals may provide an opportunity to further improve the consistent use of bisphosphonate therapy."	( Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A, 2005)	0.33
"Patients should be clearly warned that the prescribed dosing for fluticasone nasal spray should be carefully followed because overuse may cause serious side effects."	( Systemic effects of fluticasone nasal spray: report of 2 cases. Licata, AA, )	0.13
" Although bisphosphonates are effective in treatment of osteoporosis, a strict instruction to patients on the dosage often results in their inadequate compliance with the therapy."	( [Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine]. Ijiri, S, 2005)	0.33
" Nevertheless, the need to follow inconvenient dosing instructions every week could still hinder long-term compliance and therapeutic outcome."	( Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006)	0.33
"In this NH population, weekly risedronate administered using a between-meal dosing schedule reduced serum BSAP at 6 weeks of treatment; this effect was not observed at 12 weeks."	( Between-meal risedronate does not alter bone turnover in nursing home residents. Agrawal, S; Binkley, NC; Drinka, PJ; Engelke, JA; Krause, PF; Krueger, DC; Nest, LJ, 2006)	0.33
"Chronic oral-dosed osteoporosis therapies are associated with poor adherence and persistence, regardless of age or dosing regimen."	( Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA, 2006)	0.33
" The dosage regimen could be simplified by providing the two compounds in an integrated pack."	( Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. Möller, G; Ringe, JD; van der Geest, SA, 2006)	0.33
"In this multicenter, randomized, double-blind controlled trial, the efficacy and safety of once-weekly dosing with 17."	( Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. Fukunaga, M; Itabashi, A; Kishimoto, H; Kushida, K; Nakamura, T; Nawata, H; Ohashi, Y; Ohta, H; Shiraki, M; Takaoka, K, 2006)	0.33
"To compare medication persistence among patients receiving daily orally administered bisphosphonates with persistence among patients receiving weekly orally administered bisphosphonates to ascertain whether less frequent dosing is associated with better long-term treatment persistence."	( Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Ettinger, MP; Gallagher, R; MacCosbe, PE, )	0.13
"The inconvenience and complexity of required dosing procedures with oral bisphosphonate therapy for the prevention and treatment of osteoporosis are thought to be major factors that hinder medication persistence, and poor persistence is associated with suboptimal health-care outcomes."	( Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Ettinger, MP; Gallagher, R; MacCosbe, PE, )	0.13
"This study demonstrates that weekly dosing of orally administered bisphosphonates is associated with higher medication persistence than is daily dosing."	( Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Ettinger, MP; Gallagher, R; MacCosbe, PE, )	0.13
"The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis."	( Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006)	0.33
" The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate."	( Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007)	0.34
" The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used."	( Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006)	0.33
"The purpose of the present study was to examine the effect of pretreatment with risedronate and/or vitamin K2 and treatment continuation with reduced dosing frequency of the drugs on the early cancellous bone loss induced by ovariectomy (OVX) in rats."	( Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study. Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006)	0.33
"Patients preferred a weekly dosing regimen with proven vertebral and non-vertebral fracture efficacy."	( Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Gold, DT; Safi, W; Trinh, H, 2006)	0.33
" Inconvenient dosing was reported as a primary reason for discontinuation due to stopping or changing treatment in 19 (6."	( Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D, 2007)	0.34
"A stability indicating, reversed-phase ion-pair high-performance liquid chromatographic method was developed and validated for the determination of risedronate in pharmaceutical dosage forms."	( Development and validation of a reversed-phase ion-pair high-performance liquid chromatographic method for the determination of risedronate in pharmaceutical preparations. Kyriakides, D; Panderi, I, 2007)	0.34
" The dosing period was 4 weeks."	( Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats. Iwamoto, J; Sato, Y; Takeda, T; Yeh, JK, 2007)	0.34
"To examine in a major cohort of patients whether or not musculoskeletal adverse effects (MAEs), similar to those seen in intravenous bisphosphonates (BP), might occur also in high dosage oral treatment regimens with alendronate (ALN) and risedronate (RSN)."	( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM, )	0.13
" They are observed exclusively in patients starting ALN or RSN treatment with once weekly dosage regimens."	( Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. Bock, O; Boerst, H; Degner, C; Felsenberg, D; Stephan-Oelkers, M; Thomasius, FE; Valentine, SM, )	0.13
"Risedronate 150 mg once a month is similar in efficacy and safety to daily dosing and may provide an alternative for patients who prefer once-a-month oral dosing."	( Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008)	0.35
" In two groups, anterior cruciate ligament transection was performed and half were left untreated, and the other half dosed with risedronate (0."	( Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. Boyd, SK; Doschak, MR; MacNeil, JA; Zernicke, RF, 2008)	0.35
" Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule."	( Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J, 2008)	0.35
"Patients perceive less frequent dosing as being more convenient."	( Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J, 2008)	0.35
" Intravenous pamidronate is efficacious and has long been available, but its use is hindered by an impractical recommended dosing regimen of 30 mg IV over 4 h for three consecutive days."	( A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Abelson, A, 2008)	0.35
" Bisphosphonates restore normal bone turnover and relieve bone pain, but oral formulations may be limited by complicated dosing regimens and poor gastrointestinal absorption."	( A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Abelson, A, 2008)	0.35
" The effect of patient age, prescriber, initial dosing regimen, gastrointestinal adverse events, co-medication and fractures on non-compliance was investigated."	( Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008)	0.35
" Daily dosing at start, increased number of co-medications and new use of intestinal agents in the year after starting bisphosphonates were independently associated with an increased odds of non-compliance."	( Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008)	0.35
"This study revealed several determinants of non-compliance with bisphosphonates, the best controllable being the type of initial bisphosphonate, with daily dosing leading to more non-compliance than weekly dosing."	( Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008)	0.35
" Although the products are labeled to be taken in the erect position, the semisupine position was included to simulate dosing in bedridden patients."	( Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Atherton, CT; Blackshaw, PE; Dansereau, RJ; Hay, PD; Lawes, SC; Perkins, AC; Schnell, DJ; Spiller, RC; Wagner, LK, 2008)	0.35
" Strategies to improve adherence to osteoporosis therapy include reducing dosing frequency, changing the route of administration, educating the patient about optimum bisphosphonate administration, and sending patient reminders."	( Maximizing effectiveness of bisphosphonate therapy for osteoporosis. Martens, MG; Shaw, H, 2008)	0.35
" Current dosing schedules are often inconvenient or impractical for patients."	( Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Díaz-Curiel, M; Moro-Alvarez, MJ, 2008)	0.35
"5 mg risedronate, and was well tolerated with favorable safety profiles compared with once-daily dosage regimen."	( [Efficacy and tolerability of risedronate for the treatment of osteoporosis]. Kishimoto, H, 2008)	0.35
"The present study was designed to evaluate the effects of risedronate, one of the most potent bisphosphonates, on alveolar bone resorption and angiogenesis in rats with experimental periodontitis to identify dose-response curves and treatment durations that can be therapeutic for periodontal therapy versus those associated with osteonecrosis of the jaws."	( Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats. Ayas, B; Cetinkaya, BO; Gurgor, P; Keles, GC, 2008)	0.35
" Six BPs are currently approved by the US Food and Drug Administration (FDA) for the treatment of Paget disease, and each has unique characteristics, such as response rates and requirements for dosage and administration, relevant to clinical outcome."	( Paget disease of bone: therapeutic options. Silverman, SL, 2008)	0.35
" We next showed that risedronate given at a low dosage in animals bearing human B02-GFP breast tumors reduced osteolysis by inhibiting bone resorption, whereas therapy with higher doses also inhibited skeletal tumor burden."	( Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Clézardin, P; Daubiné, F; Ebetino, FH; Fournier, PG; Lundy, MW; Rogers, MJ, 2008)	0.35
" Patients remarkably preferred therapy with a proven antifracture efficacy over a dosage frequency."	( [Differences among bisfosfonates--specificity of risedronate (Actonel)]. Giljević, Z, 2008)	0.35
"Despite widely accepted efficacy of bisphophonates for osteoporotic fracture, patients treatment compliance has been low, especially, with daily regimen, in part because of the inconvenience associated with special dosing requirements of oral bisphophonates."	( [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. Okazaki, R, 2009)	0.35
" Also reviewed are results of "bridging" studies designed to demonstrate the comparable efficacy of less frequent dosing regimens to increase bone mineral density and to reduce bone turnover."	( Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Bilezikian, JP, 2009)	0.35
"Two studies in postmenopausal women with osteoporosis provide information about the efficacy and safety of dosing oral risedronate 5 mg daily at a time other than before breakfast (i."	( Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009)	0.35
"Two studies in postmenopausal women with osteoporosis provide additional information about the efficacy and safety of dosing oral risedronate 5 mg daily at a time other than before breakfast (i."	( Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009)	0.35
"One study, flexible dosing, was a 6-month North American study in 730 patients randomized to before-breakfast dosing or flexible dosing later in the day."	( Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009)	0.35
"Results of these two studies demonstrate that overall flexible dosing of risedronate leads to smaller BMD gains compared to before-breakfast dosing."	( Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009)	0.35
" Once-monthly dosing options might increase treatment compliance and persistence."	( Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. Beary, JF; Brown, JP; Burgio, DE; Darbie, LM; Matzkin, E; Racewicz, AJ; Ste-Marie, LG, 2009)	0.35
"The aim of this study was to compare the tolerability and efficacy of 3 once-monthly risedronate dosing regimens with those of risedronate 5 mg/d."	( Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. Beary, JF; Brown, JP; Burgio, DE; Darbie, LM; Matzkin, E; Racewicz, AJ; Ste-Marie, LG, 2009)	0.35
" The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed."	( Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Rackoff, P, 2009)	0.35
" Interpretations from this study are limited by assumptions of persistence based on initial drug dosing and selected refill gap length measured."	( Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Gold, DT; Safi, W; Trinh, H, 2009)	0.35
" Fracture trials were initially performed with daily formulations, then bridging trials, in which the efficacy of intermittent dosing was assessed versus daily using validated surrogate endpoints for fracture."	( Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Epstein, S; Jeglitsch, M; McCloskey, E, 2009)	0.35
" Furthermore, ibandronate has demonstrated antifracture efficacy with intermittent dosing in two pooled analyses."	( Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Epstein, S; Jeglitsch, M; McCloskey, E, 2009)	0.35
" Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose."	( Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S, 2009)	0.35
"5 mg once daily was well tolerated by patients with PDB, even though the dosage was seven times higher than that approved for the treatment of osteoporosis in Japan (2."	( Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone. Hashimoto, J; Takata, S; Yoh, K; Yoshimura, N, 2010)	0.36
" Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose."	( Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S, 2009)	0.35
" The method was validated and shown to be precise, accurate, and specific for the assay of risedronate in both bulk material and dosage forms."	( Analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography with evaporative light-scattering detection. Zhang, L, 2010)	0.36
" Anastrozole was given at a dosage of 1 mg/day while oral risedronate was given at 35 mg/week."	( Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010)	0.36
" Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important."	( Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Glendenning, P; Inderjeeth, CA; Lee, S, 2011)	0.37
" Intravenous ibandronate suppressed serum CTX levels to a significantly greater degree at 7 days after the second dosing (0."	( Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH, 2012)	0.38
" This adds to the range of risedronate dosing options and provides an alternative for patients who prefer once-a-month dosing."	( Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013)	0.39
"After 2 years, treatment with risedronate 150-mg once a month provided similar efficacy and tolerability to daily dosing and provides an alternative for patients who prefer once-a-month oral dosing."	( Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013)	0.39
" Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance."	( Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Balske, A; Burgio, DE; McClung, MR; Recker, RR; Wenderoth, D, 2013)	0.39
"A meta-analysis of spine BMD dose-response relationships for alendronate, risedronate, and ibandronate was performed."	( A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Yates, J, 2013)	0.39
"Animal data suggesting differences in potency and differences in approved oral dosage strengths for alendronate, risedronate, and ibandronate in the treatment of osteoporosis raise questions about their dose-response relationships and relative potencies in humans."	( A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Yates, J, 2013)	0.39
"A meta-analysis of dose-response relationships for spine BMD increases for these three bisphosphonates was performed using data from 21 placebo-controlled trials that collectively included over 13,000 patients on active treatment and over 8,000 on placebo."	( A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Yates, J, 2013)	0.39
" This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis."	( A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Balske, AM; Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, R; Tlustochowicz, W; Zanchetta, JR, 2013)	0.39
"Risedronate, an anti-osteoporotic drug, is associated with low patient compliance due to the upper gastrointestinal side-effects and stringent dosing regimes."	( Risedronate-loaded Eudragit S100 microparticles formulated into tablets. Cruz, L; Ferreira, LM; Mattiazzi, J; Pohlmann, L; Rolim, CM; Silva, CB; Velasquez, AA, 2014)	0.4
"We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population."	( Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2013)	0.39
" There was no relation between dosage and age (p=0."	( Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM, 2013)	0.39
"Fifty-three patients received university pharmacy blinded medication for three months: 5 mg risedronate or placebo one dosage and 1 g calcium carbonate and 800IE cholecalciferol per day."	( Risedronate does not enhance fixation or BMD in revision cups: randomised study with three years follow-up. Digas, G; Kärrholm, JN; Saari, TM, )	0.13
"This report describes bone safety and histomorphometric data across different dose levels and dosing frequencies of risedronate."	( Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG, 2015)	0.42
" The low oral bioavailability and known dosing limitations due to food interactions of bisphosphonates have led to development of an oral delayed-release dose form of risedronate 35 mg to be taken weekly, before or after breakfast."	( Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG, 2015)	0.42
"Minodronate is a potent nitrogen-containing bisphosphonate that can be administered according to a monthly (every 4 weeks) dosing regimen."	( Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO). Furuya, T; Hasegawa, M; Hirabayashi, H; Iwamoto, J; Kumakubo, T; Makita, K; Okano, H; Urano, T, 2016)	0.43
"The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1)."	( Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study. Lorenc, R; Oral, A, 2015)	0.42
"A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP."	( Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study. Lorenc, R; Oral, A, 2015)	0.42
" In this 1-year, randomized, double-blind, multicenter study we compared the weekly 35-mg and daily 5-mg risedronate dosing regimens in the treatment of Chinese postmenopausal women with osteoporosis or osteopenia."	( The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Chen, DC; Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Jin, XL; Lin, H; Liu, YJ; Tang, H; Wang, C; Wang, L; Xia, WB; Yue, H; Zhang, H; Zhang, ZL, 2015)	0.42
"The weekly 35-mg and daily 5-mg risedronate dosing regimens during 1 year of follow-up show similar efficacy in improving BMDs and biochemical markers of bone turnover in Chinese postmenopausal women with osteoporosis or osteopenia."	( The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Chen, DC; Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Jin, XL; Lin, H; Liu, YJ; Tang, H; Wang, C; Wang, L; Xia, WB; Yue, H; Zhang, H; Zhang, ZL, 2015)	0.42
" In the present study, to increase oral BA of the bisphosphonate, a novel enteric-coated tablet (ECT) dosage form of RS in combination with phytic acid (IP6), a natural chelating agent recognized as safe, was formulated."	( Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. Jang, SW; Kang, MJ; Kim, BM; Kim, JS; Son, M, 2016)	0.43
"This retrospective, observational study assessed 2-year persistence and compliance by treatment, route of administration, and dosing frequency in postmenopausal women initiating a new osteoporosis therapy."	( Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Barron, R; Durden, E; Juneau, P; Lopez-Gonzalez, L; Pinto, L, 2017)	0.46
" Multivariable logistic regression was used to compare the odds of persistence and compliance across treatment and dosing regimens."	( Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Barron, R; Durden, E; Juneau, P; Lopez-Gonzalez, L; Pinto, L, 2017)	0.46
" Patients initiating an every-6-month injection had significantly higher persistence compared with those initiating more frequently dosed (e."	( Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Barron, R; Durden, E; Juneau, P; Lopez-Gonzalez, L; Pinto, L, 2017)	0.46
" In the zoledronate group, mean PINP 6 months post-FRAME was 23 ± 4 µg/L and at 12 months it was 47 ± 8 µg/L, suggesting that repeat zoledronate dosing is needed at 1 year to maintain the BMD gains."	( Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates. Horne, AM; Mihov, B; Reid, IR, 2018)	0.48
" Whenever the initial dose failed to produce remission, the dosage was increased to twice a week the respective dose."	( Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting. Abu Tailakh, M; Liel, Y, 2019)	0.51
"The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France."	( Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. Hiligsmann, M; Reginster, JY, 2019)	0.51
" Simulations revealed the high variability in the concentration levels after different dosage schemes."	( Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Cardozo, B; Karalis, V; Karatza, E, 2021)	0.62
" Simulations are used to compare the risedronate plasma levels after different dosage schemes and assess the need for dose adjustment in patients with impaired kidney functionality."	( Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Cardozo, B; Karalis, V; Karatza, E, 2021)	0.62
" Simulations revealed the high discrepancy in the concentration levels observed after different dosage regimens, implying the safety profile of risedronate."	( Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Cardozo, B; Karalis, V; Karatza, E, 2021)	0.62
" Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy."	( Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022)	0.72
"Up to half of patients do not follow complex dosing instructions of immediate-release bisphosphonates used for the prevention of osteoporotic fractures, which can result in suboptimal effectiveness."	( Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022)	0.72
" In addition, we looked at benefit and harm comparisons between different dosage regimens for risedronate and between risedronate and other anti-osteoporotic drugs."	( Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Hsieh, SC; Liu, W; Peterson, J; Tugwell, P; Wells, GA; Zheng, C, 2022)	0.72
" Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms."	( Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Al-Daghri, N; Bock, O; Branco, J; Bruyère, O; Casado, E; Cavalier, E; Cooper, C; Cortet, B; de Wit, M; Fuggle, N; Giusti, A; Halbout, P; Harvey, NC; Hiligsmann, M; Kanis, JA; Kaufman, JM; Kurth, A; Maggi, S; Matijevic, R; Minisola, S; Palacios, S; Radermecker, RP; Reginster, JY; Rizzoli, R; Thomasius, F; Tuzun, S; Veronese, N, 2022)	0.72

Class	Description
pyridines	Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
geranyl diphosphate biosynthesis	6	7
Mevalonate arm of cholesterol biosynthesis pathway with inhibitors	2	14

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)	IC50 (µMol)	75,195.2825	0.0040	1.0276	4.5000	AID1798541; AID576219; AID669079; AID74507
Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)	Ki	8,300.0000	1.8000	2.2500	2.7000	AID576219
Farnesyl pyrophosphate synthase	Homo sapiens (human)	IC50 (µMol)	0.1104	0.0002	0.7109	9.3600	AID1054150; AID1054151; AID1197852; AID1204204; AID1205922; AID1205923; AID1224396; AID1421103; AID1519530; AID318593; AID318594; AID332041; AID516764; AID669074; AID669076; AID685336; AID689987; AID72181; AID72667; AID72669
Farnesyl pyrophosphate synthase	Homo sapiens (human)	Ki	0.0329	0.0001	0.2165	1.9000	AID318593; AID318594; AID72668
Farnesyl pyrophosphate synthase	Leishmania donovani	IC50 (µMol)	0.1699	0.1100	0.1560	0.1700	AID259378; AID72651
Farnesyl pyrophosphate synthase	Leishmania donovani	Ki	0.0170	0.0110	0.0782	0.1900	AID238531
Farnesyl diphosphate synthase	Toxoplasma gondii	IC50 (µMol)	0.0740	0.0740	0.0740	0.0740	AID593263; AID726609
Farnesyl pyrophosphate synthase	Leishmania major	Ki	0.0160	0.0100	0.0390	0.0910	AID1697964
H	Trypanosoma brucei	IC50 (µMol)	656.7000	2.1000	2.1000	2.1000	AID254970
Farnesyl diphosphate synthase	Trypanosoma cruzi	IC50 (µMol)	0.0270	0.0270	0.0270	0.0270	AID593262; AID726611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Butyrophilin subfamily 3 member A1	Homo sapiens (human)	EC50 (µMol)	0.0800	0.0001	0.4719	3.0600	AID1676487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of cytokine production	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
adaptive immune response	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
positive regulation of type II interferon production	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
activated T cell proliferation	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
T cell receptor signaling pathway	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
regulation of cytokine production	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
isoprenoid metabolic process	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
geranyl diphosphate biosynthetic process	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
geranylgeranyl diphosphate biosynthetic process	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
farnesyl diphosphate biosynthetic process	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
isoprenoid biosynthetic process	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
cholesterol biosynthetic process	Farnesyl pyrophosphate synthase	Homo sapiens (human)
geranyl diphosphate biosynthetic process	Farnesyl pyrophosphate synthase	Homo sapiens (human)
farnesyl diphosphate biosynthetic process	Farnesyl pyrophosphate synthase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
signaling receptor binding	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
dimethylallyltranstransferase activity	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
farnesyltranstransferase activity	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
geranyltranstransferase activity	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
protein binding	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
identical protein binding	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
metal ion binding	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
prenyltransferase activity	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
RNA binding	Farnesyl pyrophosphate synthase	Homo sapiens (human)
protein binding	Farnesyl pyrophosphate synthase	Homo sapiens (human)
metal ion binding	Farnesyl pyrophosphate synthase	Homo sapiens (human)
dimethylallyltranstransferase activity	Farnesyl pyrophosphate synthase	Homo sapiens (human)
geranyltranstransferase activity	Farnesyl pyrophosphate synthase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
external side of plasma membrane	Butyrophilin subfamily 3 member A1	Homo sapiens (human)
nucleoplasm	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
cytoplasm	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
cytosol	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
Z disc	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
perinuclear region of cytoplasm	Geranylgeranyl pyrophosphate synthase	Homo sapiens (human)
nucleoplasm	Farnesyl pyrophosphate synthase	Homo sapiens (human)
cytosol	Farnesyl pyrophosphate synthase	Homo sapiens (human)
cytoplasm	Farnesyl pyrophosphate synthase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1061018	Inhibition of Toxoplasma gondii recombinant FPPS expressed in Escherichia coli using [4-14C]IPP/DMAPP/GPP as substrate after 30 mins by scintillation counting analysis	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.
AID1744121	Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID1421099	Inhibition of recombinant human C-terminal His6-tagged GGPPS expressed in Escherichia coli BL21 at 100 uM using IPP and FPP as substrates pretreated for 15 mins followed by substrates addition and measured after 1 hr by colorimetric method relative to con	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID480318	Inhibition of RGGT-mediated Rap1A prenylation in mouse J774 cells after 24 hrs by Western blot analysis	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
AID1421112	Induction of mineralization in mouse MC3T3-E1 cells at >500 nM after 10 to 15 days by alizarin red dye based assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID348330	Antiinflammatory activity in delayed type hypersensitivity rat model assessed as inhibition of granuloma dry weight at 100 mg/kg, sc	2008	European journal of medicinal chemistry, May, Volume: 43, Issue:5	Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1421093	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID1224404	Cytotoxicity against human SH-SY5Y cells assessed as LDH release after 48 hrs (Rvb = 0%)	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.
AID1421104	Binding affinity to hydroxyapatite at 100 uM using sodium salt form of compound after 5 mins by ESI/MS analysis	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID576218	Inhibition of Plasmodium vivax FPPS	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID238531	Binding affinity towards Farnesyl diphosphate synthase from leishmania major	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
AID72669	Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M)	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID669076	Inhibition of human recombinant N-terminal-His6 tagged FPPS expressed in Escherichia coli BL21 using [3H]IPP and GPP as substrate measured after 20 mins by liquid scintillation counting	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID248772	In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID1421107	Induction of mineralization in C57BL mouse bone marrow cells co-cultured with human PC3 cells at 50 to 100 nM supplemented with fresh medium containing compound every 3 days for 10 to 15 days by alizarin red dye based assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID72667	Inhibitory activity against farnesyl Pyrophosphate Synthase was determined	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID1054147	Binding affinity to bone mineral hydroxyapatite at 50 uM after 5 mins by NMR-spectroscopic analysis	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
AID303798	Bone mineral affinity on hydroxyaptite assessed as retention time by chromatography	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
AID229223	Percent infected vero cells was determined	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID669083	Antiproliferative activity against human KMS-28PE after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
AID213660	In vitro antiparasitic activity against Trypanosoma cruzi (amastigotes)	2001	Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6	Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
AID74507	Inhibitory activity against the human recombinant geranylgeranyl diphosphate synthase (GGPPSase).	2002	Journal of medicinal chemistry, May-23, Volume: 45, Issue:11	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
AID158550	In vitro growth inhibition against Plasmodium falciparum	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID1204204	Inhibition of FDPS (unknown origin)	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation.
AID593262	Inhibition of Trypanosoma cruzi FPPS after 30 mins using [14C]IPP by scintillation counting	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.
AID259378	Inhibitory activity against FPPS in Leishmania major	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID55429	Ability to inhibit growth of Dictostelium discoideum.	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
AID576004	Antiplasmodial activity against Plasmodium berghei NK65 infected in 12 wk old C57BL/6 mouse assessed as prepatent period at 20 mg/kg, ip administered once daily via a regimen of day 1 pre-infection, on the day of infection followed by day 1 postinfection	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID348327	Antiinflammatory activity in delayed type hypersensitivity rat model assessed as inhibition of granuloma wet weight at 100 mg/kg, sc	2008	European journal of medicinal chemistry, May, Volume: 43, Issue:5	Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID151353	Inhibition of Plasmodium falciparum 3D7 in erythrocytes	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID1421102	Inhibition of recombinant human C-terminal His6-tagged FPPS expressed in Escherichia coli BL21 at 1 uM using DMAPP and IPP as substrates pretreated for 15 mins followed by substrates addition and measured after 1 hr by colorimetric method relative to cont	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID208081	50% inhibitory concentration against Trypanosoma brucei rhodesiense	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID576002	Antiplasmodial activity against Plasmodium berghei NK65 infected in 8 wk old C57BL/6 mouse assessed as prepatent period at 20 mg/kg, ip administered once daily via a regimen of day 1 pre-infection, on the day of infection followed by day 1, 2 and 3 days p	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID1697964	Inhibition of recombinant Leishmania major FPPS expressed in Escherichia coli BL21(DE3) using GPP and [14C]IPP as substrate incubated for 15 mins by scintillation counting method	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	A guanidinium-based inhibitor of a type I isopentenyl diphosphate isomerase.
AID575995	Cytotoxicity against human HepG2 cells after 22 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID332041	Inhibition of human FPPS	2008	Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9	Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.
AID318593	Inhibition of human recombinant FPPS expressed in Escherichia coli BL21	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID1224403	Inhibition of FPPS in human SH-SY5Y cells assessed as blocking of tau metabolism by measuring ratio of tau phosphorylation to total tau level at 100 nM after 24 hrs by ELISA (Rvb = 0.012 no-unit)	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.
AID255448	Ratio of ED50 against KB cell line to that of IC50 of TbVSP1	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
AID1061026	Antimicrobial activity against Trypanosoma cruzi CL amastigotes infected in african green monkey Vero cells measured on day 3 by fluorescence assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.
AID254970	Inhibition of recombinant Trypanosoma brucei soluble vacuolar pyrophosphatase expressed in Escherichia coli	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
AID1224397	Binding affinity to human FPPS assessed as change in thermal unfolding by differential scanning fluorimetry	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.
AID1091882	Inhibition of Aquifex aeolicus IspH expressed in Escherichia coli BL21 (DE3) using HMBPP substrate	2010	Journal of the American Chemical Society, May-19, Volume: 132, Issue:19	Inhibition of the Fe(4)S(4)-cluster-containing protein IspH (LytB): electron paramagnetic resonance, metallacycles, and mechanisms.
AID1205922	Inhibition of human FPPS in absence of pre-incubation of compound with enzyme	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1054151	Inhibition of human recombinant FPPS using GPP/[3H]IPP as substrate incubated for 10 mins prior to substrate addition by scintillation counting analysis	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
AID576221	Partition coefficient, log P of the compound	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID208203	In vitro rescue of growth inhibition of Trypanosoma uM of compound	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID576227	Antiplasmodial activity against Plasmodium berghei NK65 infected in 12 wk old BALB/c mouse assessed as prepatent period assessed as complete suppression of parasitemia at 20 mg/kg, ip administered once daily via a regimen of day 2, 1 pre-infection, on the	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID208217	Predicted pIC50 against Trypomastigotes Brucei rhodesiense.	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID576208	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as suppression of parasitemia by microscopic analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID1197855	Competitive inhibition of human HPPS at 100 uM by NMR analysis in presence of Mg2+	2015	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5	Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase.
AID303800	Reduction of viability of mouse J744 cells after 48 hrs	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID575996	Therapeutic index, ratio of TC50 for human HepG2 cells to IC50 for Plasmodium berghei NK65	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID1774079	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID318594	Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID1421090	Antiproliferative activity against mouse J774A.1 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID593263	Inhibition of Toxoplasma gondii FPPS after 30 mins using [14C]IPP by scintillation counting	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.
AID72668	Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID576006	Antiplasmodial activity against Plasmodium berghei NK65 infected in 12 wk old C57BL/6 mouse assessed as prepatent period at 10 mg/kg, ip administered once daily via a regimen of day 1 pre-infection, on the day of infection followed by day 1 postinfection	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID669079	Inhibition of human recombinant N-terminal His6 tagged GGPPS expressed in Escherichia coli BL21 using FPP and [14C]IPP as substrate incubated for 10 mins prior to substrate addition by scintillation counting	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID340434	Antimicrobial activity against Dictyostelium discoideum	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
AID340427	Inhibition of farnesyl diphosphate synthase at 2 nM	2008	Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14	Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
AID256540	Dose to inhibit the growth of human KB carcinoma cell line	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
AID726609	Inhibition of Toxoplasma gondii farnesyl diphosphate synthase assessed as incorporation of [4-14C]IPP measured at 37 degC	2013	European journal of medicinal chemistry, Feb, Volume: 60	Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID184809	Bone resorption activity in rats.	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
AID235248	Therapeutic index was expressed as ratio of LD50 for KB cell line to IC50 against Plasmodium falciparum	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID480321	Inhibition of GGPPS after 10 mins using [14C]IPP as substrate by liquid scintillation counting	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
AID214470	Effect on inhibition on proliferation of Trypanosoma cruzi Amastigotes in vero cells at a conc of 150 uM	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID1421113	Induction of mineralization in C57BL mouse bone marrow cells at >50 nM supplemented with fresh medium containing compound every 3 days for 10 to 15 days by alizarin red dye based assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID72651	Inhibitory activity against Leishmania major Farnesyl diphosphate synthase	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID721279	Inhibition of recombinant GGTase 2 (unknown origin) by scintillation counting in presence of [3H]GGPP	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Triazole-based inhibitors of geranylgeranyltransferase II.
AID1054150	Inhibition of human recombinant FPPS using GPP/[3H]IPP as substrate incubated for 10 mins prior to substrate addition measured after 8 mins by scintillation counting analysis	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
AID689987	Inhibition of recombinant human FPPS expressed in Escherichia coli by scintillation counting	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID259377	Cytotoxicity to Dictyostelium discoideum	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
AID1421094	Antiproliferative activity against RANKL-differentiated mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by CCK8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID326145	Inhibition of Escherichia coli UPPS	2007	Proceedings of the National Academy of Sciences of the United States of America, Jun-12, Volume: 104, Issue:24	Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.
AID1421106	Induction of mineralization in C57BL mouse bone marrow cells at 50 nM supplemented with fresh medium containing compound every 3 days for 10 to 15 days by alizarin red dye based assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID576217	Inhibition of Plasmodium vivax GGPPS	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID259374	Inhibitory activity against Trypanosoma cruzi hexokinase	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
AID1774075	Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID689988	Inhibition of bone resorption in rat	2011	Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17	Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.
AID576003	Antiplasmodial activity against Plasmodium berghei NK65 infected in 8 wk old C57BL/6 mouse assessed as prepatent period at 20 mg/kg, ip administered once daily via regimen of 2 and 1 day post infection, on the day of infection followed by day 1 postinfect	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID246048	Effective concentration against human Gamma delta T cells	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
AID669081	Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
AID71578	Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL	2004	Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2	Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
AID576222	Antiplasmodial activity against 3000 Plasmodium berghei NK65 liver stage sporozoites infected in 12 wk old C57BL/6 mouse assessed as delay in prepatent period at 20 mg/kg, ip administered once daily via a regimen of day 2, 1 pre-infection, on the day of i	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1421103	Inhibition of recombinant human C-terminal His6-tagged FPPS expressed in Escherichia coli BL21 using DMAPP and IPP as substrates pretreated for 15 mins followed by substrates addition and measured after 1 hr by colorimetric method	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID726611	Inhibition of Trypanosoma cruzi farnesyl diphosphate synthase assessed as incorporation of [4-14C]IPP measured at 37 degC	2013	European journal of medicinal chemistry, Feb, Volume: 60	Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID208225	Inhibition of Trypanosoma rhodesiense (strain STIB900) was determined using blood stream from trypomastigotes	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID412957	Inhibition of Plasmodium vivax FPPS expressed in Escherichia coli BL21 by spectrophotometric assay	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data.
AID303801	Inhibition of RGGT mediated Rap1A prenylation in J744 cells	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
AID576209	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2mef assessed as suppression of parasitemia by microscopic analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID480330	Inhibition of human FPPS assessed as Ras farnesylation up to 400 uM after 10 mins using [14C]mevalonate as substrate	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
AID72181	Inhibitory activity against the human recombinant FPPSase (Farnesyl diphosphate) enzyme	2002	Journal of medicinal chemistry, May-23, Volume: 45, Issue:11	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID326146	Inhibition of Sulfolobus solfataricus HPPS	2007	Proceedings of the National Academy of Sciences of the United States of America, Jun-12, Volume: 104, Issue:24	Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.
AID1421114	Induction of mineralization in C57BL mouse bone marrow cells co-cultured with human PC3 cells at >100 nM supplemented with fresh medium containing compound every 3 days for 10 to 15 days by alizarin red dye based assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID235247	Therapeutic index was expressed as ratio of LD50 for KB cell line to IC50 against Entamoeba histolytica	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID575998	Antiplasmodial activity against Plasmodium berghei NK65 infected in 12 wk old BALB/c mouse assessed as prepatent period at 20 mg/kg, ip administered once daily via regimen of 1 preinfection, on day of infection followed by regimen of 1 day post infection	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID235219	Therapeutic index measured as the ratio of LD50 (KB cells) to IC50 (T.b. rhodesiense)	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID1744122	Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)	2021	Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1	Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID576220	Inhibition of human FPPS	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID726610	Antiparasitic activity against Trypanosoma cruzi amastigotes infected in gamma-irradiated vero cells assessed as growth inhibition measured after 3 days by fluorescence assay	2013	European journal of medicinal chemistry, Feb, Volume: 60	Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
AID71579	Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release	2004	Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2	Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
AID669075	Inhibition of human recombinant N-terminal-His6 tagged FPPS expressed in Escherichia coli BL21 using [3H]IPP and GPP as substrate at 1 uM incubated for 10 mins prior to substrate addition measured after 20 mins by liquid scintillation counting	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
AID576212	Antiplasmodial activity against 5 X 10'6 blood stream Plasmodium berghei NK65 infected in 12 wk old C57BL/6 mouse assessed as delay in prepatent period at 20 mg/kg, ip administered once daily via a regimen of day 2, 1 pre-infection, on the day of infectio	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID270723	Antiproliferative activity against human NCI-H460 cell line by MTT assay	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
AID669094	Ratio of IC50 for human recombinant FPPS without compound preincubation to IC50 for human recombinant FPPS with compound preincubation	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
AID1245160	Binding affinity to FPPS (unknown origin) in presence of isopentenyl pyrophosphate and in presence of Mg2+ ions by neutron protein crystallography	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase.
AID576005	Antiplasmodial activity against Plasmodium berghei NK65 infected in 12 wk old C57BL/6 mouse assessed as prepatent period at 10 mg/kg, ip administered once daily via a regimen of day 2, 1 days pre-infection, on the day of infection followed by day 1 postin	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID726608	Antiparasitic activity against Toxoplasma gondii tachyzoite expressing red fluorescence protein assessed as growth inhibition by fluorescence plate reader	2013	European journal of medicinal chemistry, Feb, Volume: 60	Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents.
AID95764	Inhibition of L. donovani (Amastigotes) strain MHOM/ET/67/L82 maintained in female golden hamsters	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID259375	Cytotoxicity in human nasopharyngeal carcinoma KB cell line	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
AID208205	In vitro rescue of growth inhibition of Trypanosoma uM of compound	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID516764	Inhibition of N-terminal His-tagged human FPPS expressed in Escherichia coli	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.
AID1676487	Binding affinity to BTN3A1 in human PBMC-derived Vgamma9/Vdelta2 T cells
AID1421092	Antiproliferative activity against human MG63 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1224396	Allosteric inhibition of human recombinant FPPS using GPP and [3H]IPP as substrate incubated with enzyme for 10 mins prior to substrate addition by liquid scintillation counting analysis	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.
AID208207	In vitro rescue of growth inhibition of Trypanosoma uM of compound	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID1197852	Inhibition of human FPPS	2015	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5	Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1519530	Inhibition of FDPS (unknown origin)	2019	Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24	Novel benzimidazole phosphonates as potential inhibitors of protein prenylation.
AID158476	Inhibitory activity against Entamoeba histolytica pyrophosphate-dependent phosphofructokinase (PFK)	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID249161	Lethal dose required to inhibit the growth of human KB (nasopharyngeal carcinoma) cell line	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID1774076	Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1054148	Inhibition of human recombinant FPPS using GPP/[3H]IPP as substrate up to 10 uM incubated for 10 mins prior to substrate addition measured after 8 mins by scintillation counting analysis	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
AID1421097	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells after 72 hrs by TRAP staining based microscopic analysis	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID1699996	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility.
AID1774078	Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method	2021	Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19	Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1205920	Inhibition of Trypanosoma brucei FPPS	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries.
AID93828	50% lethal dose for inhibition of KB cells growth	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID208084	In vitro growth inhibition of bloodstream-form Trypanosoma brucei rhodesiense Trypomastigotes	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID318595	Inhibition of bone resorption in rat assessed as phosphate	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID96034	Toxicity evaluated against human nasopharyngeal carcinoma KB cell line	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID412958	Growth inhibition of Plasmodium falciparum	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1054146	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
AID1224398	Binding affinity to human FPPS assessed as change in thermal unfolding by differential scanning fluorimetry in presence of IPP and Mg2+	2014	Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13	Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.
AID1245159	Binding affinity to FPPS (unknown origin) in presence of Mg2+ ions by neutron protein crystallography	2015	Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18	Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase.
AID1421108	Cytotoxicity against C57BL mouse bone marrow cells assessed as effect on cell proliferation at 0.03 to 500 uM after 72 hrs by crystal violet staining based assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID576219	Inhibition of human GGPPS	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1205923	Inhibition of human FPPS using pre-incubation of compound with enzyme	2015	ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3	Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries.
AID247940	Inhibitory concentration against Dictyostelium discoideum cell growth	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
AID275054	Antibacterial activity against Escherichia coli W3110	2006	Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25	Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID576001	Antiplasmodial activity against Plasmodium berghei NK65 infected in 12 wk old BALB/c mouse assessed as prepatent period at 17 mg/kg, ip administered once daily on the day of infection followed by day 1 postinfection for 2 days by microscopic analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID576215	Antiplasmodial activity against 5 X 10'6 blood stream Plasmodium berghei NK65 infected in 12 wk old C57BL/6 mouse assessed as parasitemia at 20 mg/kg, ip administered once daily via a regimen of day 2, 1 pre-infection, on the day of infection followed by	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID1061022	Antimicrobial activity against Toxoplasma gondii tachyzoites expressing red fluorescence protein infected in hTerT cells measured daily by fluorescence assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1061019	Inhibition of Trypanosoma cruzi recombinant FPPS assessed as incorporation of [4-14C]IPP with DMAPP into [4-14C]FPP after 30 mins by scintillation counting analysis	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID270725	Antiproliferative activity against rat 13762 cell line	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
AID576000	Antiplasmodial activity against Plasmodium berghei NK65 infected in 12 wk old BALB/c mouse assessed as prepatent period at 5 mg/kg, ip administered once daily on the day of infection followed by day 1 postinfection for 2 days by microscopic analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID480322	Inhibition of GGTase1 assessed as incorporation of [3H]GGPP into His-tagged canine rab1a after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
AID244679	Therapeutic index (TI) value as ratio of lethal dose (LD50) to the inhibitory concentration (IC50)	2005	Journal of medicinal chemistry, May-05, Volume: 48, Issue:9	Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID576211	Antiplasmodial activity against 5 X 10'6 blood stream Plasmodium berghei NK65 infected in 12 wk old C57BL/6 mouse assessed as prepatent period at 20 mg/kg, ip administered once daily via a regimen of day 2, 1 pre-infection, on the day of infection followe	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID326147	Inhibition of Escherichia coli OPPS	2007	Proceedings of the National Academy of Sciences of the United States of America, Jun-12, Volume: 104, Issue:24	Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.
AID1421091	Antiproliferative activity against mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
AID259376	Therapeutic index TI=LD50(KB)/IC50(TcHK)	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1054145	Ratio of IC50 for human recombinant FPPS incubated for 10 mins prior to substrate addition by scintillation counting analysis to IC50 for human recombinant FPPS incubated for 10 mins prior to substrate addition measured after 8 mins by scintillation count	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
AID248139	In vitro inhibitory concentration against bone resorption in 17 day old fetal mouse metatarsals	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
AID214469	Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID71580	pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL	2004	Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2	Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID270724	Antiproliferative activity against human SF-268 cell line by MTT assay	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
AID208204	In vitro rescue of growth inhibition of Trypanosoma uM of compound	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID270722	Antiproliferative activity against human MCF7 cell line by MTT assay	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID685336	Inhibition of human His6-tagged recombinant FPPS expressed in Escherichia coli BL21(DE3) using GPP and [3H]IPP as substrate incubated for 5 mins prior to substrate addition measured after 20 mins by liquid scintillation counting	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1894079	Anti-osteoclast activity rat assessed as inhibition of bone resorption relative to control	2021	Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3	Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID67525	In vitro growth inhibition against Entamoeba histolytica	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID480317	Inhibition of RGGT-mediated Rab11 prenylation in mouse J774 cells after 24 hrs by Western blot analysis	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
AID208202	In vitro rescue of growth inhibition of Trypanosoma uM of compound	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID575994	Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.
AID208208	In vitro rescue of growth inhibition of Trypanosoma uM of compound	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
AID685337	Inhibition of human N-terminal His6-tagged recombinant human GGPS expressed in Escherichia coli BL21(DE3) using FPP and [14C]IPP as substrate at 10 uM by scintillation counting	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls.
AID669074	Inhibition of human recombinant N-terminal-His6 tagged FPPS expressed in Escherichia coli BL21 using [14C]IPP and GPP as substrate incubated for 10 mins prior to substrate addition measured after 10 mins by scintillation counting	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
AID71581	pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release	2004	Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2	Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
AID210617	Inhibition of Toxoplasma gondii tachyzoites in human foreskin fibroblast monolayer(DMEM with 10%fetal calf serum)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1799536	Enzymatic Assay from Article 10.1016/j.chembiol.2008.10.017: \\Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis.\\	2008	Chemistry & biology, Dec-22, Volume: 15, Issue:12	Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis.
AID1798541	GGPP Synthase Inhibition Assay from Article 10.1021/jm800325y: \\Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.\\	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	66 (5.25)	18.2507
2000's	633 (50.40)	29.6817
2010's	465 (37.02)	24.3611
2020's	92 (7.32)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	290 (22.00%)	5.53%
Reviews	215 (16.31%)	6.00%
Case Studies	66 (5.01%)	4.05%
Observational	16 (1.21%)	0.25%
Other	731 (55.46%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (95)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density i [NCT01215890]	Phase 4	0 participants	Interventional		Completed
Randomized, Double-blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observational Period [NCT00051636]	Phase 3	172 participants (Actual)	Interventional	2001-01-31	Completed
A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis [NCT00092014]	Phase 3	1,053 participants (Actual)	Interventional	2002-09-01	Completed
Effect of Bisphosphonate Use on Surgical Weight Loss Associated Bone Loss in Older Adults With Morbid Obesity [NCT03411902]	Phase 4	24 participants (Actual)	Interventional	2018-06-15	Completed
Effect of Actonel on Periodontal Health of Postmenopausal Women [NCT00594334]	Phase 4	0 participants (Actual)	Interventional	2008-01-31	Withdrawn(stopped due to Never started)
Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta? [NCT03208582]	Phase 2	13 participants (Actual)	Interventional	2017-04-01	Completed
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double [NCT00092040]	Phase 3	936 participants (Actual)	Interventional	2003-03-18	Completed
A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures [NCT02148848]	Phase 4	86 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Randomized, Double-Blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observation Period [NCT00103740]	Phase 3	185 participants (Actual)	Interventional	2002-04-30	Completed
The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women [NCT01077817]		684,815 participants (Actual)	Observational	2010-02-26	Completed
Food Effects on the Relative Bioavailability of a Risedronate 20 mg Delayed-release [DR] Tablet and to Compare the 20 mg DR Tablet to 35 mg DR and 35 mg Immediate-release Tablets [NCT00717145]	Phase 1	94 participants (Actual)	Interventional	2008-07-31	Completed
Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis [NCT00632216]	Phase 4	464 participants (Actual)	Interventional	2004-05-31	Completed
Two-year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study [NCT00619957]	Phase 3	285 participants (Actual)	Interventional	2002-06-30	Completed
A Multicenter, Open-label, Single-arm Clinical Trial to Evaluate the Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women [NCT05630768]	Phase 4	155 participants (Anticipated)	Interventional	2023-01-03	Recruiting
A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, & 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis. [NCT00541658]	Phase 3	923 participants (Actual)	Interventional	2007-10-31	Completed
A Randomized, Double Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) [NCT00452439]	Phase 3	72 participants (Actual)	Interventional	2004-02-29	Completed
Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant [NCT00266708]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2002-10-31	Completed
Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine BMD (Bone Mineral Density) in Men and Postmenopausal Women With Low Bone Mass and a Recent Pertrochanteric Hip Fracture [NCT00887354]	Phase 4	224 participants (Actual)	Interventional	2009-04-30	Completed
A 2-year Randomised Parallel Group Trial of Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care. [NCT00666627]	Phase 2	410 participants (Anticipated)	Interventional	2007-04-30	Completed
A Randomized Multicenter Parallel Group Study to Determine if Knowledge of Baseline Vertebral Fracture Prevalence (as Determined by Hologic IVA) and Bone Turnover Marker Determinations Improves Persistence With Actonel 5mg Daily Therapy in Subjects Receiv [NCT00616694]	Phase 4	248 participants (Actual)	Interventional	2002-07-31	Completed
Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer. [NCT00859703]	Phase 3	20 participants (Actual)	Interventional	2009-11-30	Completed
A Crossover Study to Assess the Relative BA of Delayed-release Risedronate Compared When Dosed With Either Dinner, Breakfast or Breakfast Plus a Calcium/Vitamin D Tablet [NCT00868907]	Phase 1	101 participants (Actual)	Interventional	2009-03-31	Completed
The Effect of Teriparatide Compared With Risedronate on Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures [NCT00343252]	Phase 3	712 participants (Actual)	Interventional	2006-06-30	Completed
Influence of a High-fat Meal on the Bioavailability of a Two Different Formulations of Risedronate [NCT00755872]	Phase 1	76 participants (Actual)	Interventional	2007-11-30	Completed
A 12-month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing 150 mg Once-a-month Risedronate and Placebo Using 3-dimensional Micro MRI (Magnetic Resonance Imaging). [NCT00577395]	Phase 4	13 participants (Actual)	Interventional	2008-07-31	Terminated
Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study [NCT00772395]	Phase 4	78 participants (Actual)	Interventional	2006-04-30	Completed
An 18-Month, Multicenter, Parallel-Group Study to Determine The Relative Efficacy of Risedronate Versus Raloxifene in Subjects Who Have Discontinued Hormone Replacement Therapy (HRT) for Early Intervention in Osteoporosis [NCT00790101]	Phase 4	6 participants (Actual)	Interventional	2004-06-30	Terminated
Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis Double-blind Randomized Study Versus Placebo [NCT02744482]	Phase 3	3 participants (Actual)	Interventional	2016-05-31	Terminated(stopped due to lack of patients)
Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study [NCT00549068]	Phase 4	2,433 participants (Actual)	Interventional	2003-02-28	Completed
A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg [NCT00549965]	Phase 4	202 participants (Actual)	Interventional	2003-10-31	Completed
Reconnecting: Improving Interoception to Reduce Suicidal Ideation in the Military [NCT04103385]		195 participants (Actual)	Interventional	2020-06-01	Completed
For 12months, the Multi Center, Randomized, Open-label Comparative Clinical Study to Evaluate the Efficacy and the Safety of Monthly(RisenexM Group) Versus Weekly Oral Risedronate(Risenexsplus Group) With Vitamin D in Compliance, Improvement of Vitamin D [NCT01904110]	Phase 4	196 participants (Actual)	Interventional	2012-12-31	Completed
Record on Satisfaction of Patients With Actonel 35 mg Once a Week [NCT00544180]	Phase 4	7 participants (Actual)	Interventional	2005-05-31	Terminated(stopped due to The trial was terminated due to lack of compliance with GCP regulations.)
An Open Label, International, Multi Centre, Parallel Group, Phase III b, Randomised Trial, Investigating Lumbar Spine Bone Mineral Density (BMD) Changes in Postmenopausal Women With Primary Osteoporosis Initially Treated With 12 Months of Full Length Para [NCT00365456]	Phase 3	407 participants (Actual)	Interventional	2006-07-31	Completed
A Non-Invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D-Peripheral Quantitative Computed Tomography (3D-pQCT) [NCT00386360]	Phase 3	161 participants (Actual)	Interventional	2006-04-30	Completed
Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men [NCT00503399]	Phase 3	92 participants (Actual)	Interventional	2007-07-31	Completed
Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study. [NCT00377234]	Phase 4	356 participants (Actual)	Interventional	2006-05-31	Completed
Évaluation Multidimensionnelle de la réponse au Traitement de l'ostéoporose spontanée et Induite Par Les corticostéroïdes à l'Aide d'un Bisphosphonate à Administration Orale Chez Des Malades Porteurs d'Une Dystrophie Musculaire sévère. [NCT01882400]	Phase 4	11 participants (Actual)	Interventional	2001-05-31	Completed
An Extension Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO [NCT00577421]	Phase 3	32 participants (Actual)	Interventional	2003-06-30	Completed
Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis [NCT00577850]	Phase 1	32 participants (Actual)	Interventional	2002-11-30	Completed
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone [NCT00445575]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2007-07-22	Completed
Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Risedronate Daily or Weekly [NCT00837746]		29 participants (Actual)	Observational	2003-04-30	Completed
A Randomized, Open-label, 2-period, Crossover Study to Assess the Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets Administered as a Single Oral Dose in Healthy Male and Female Subjects [NCT00699777]	Phase 1	96 participants (Actual)	Interventional	2008-01-31	Completed
Study to Assess the Efficacy, Safety and Pharmacokinetics of Risedronate Upon Oral Administration of a 35 mg Delayed-Release, a 50 mg Delayed-Release or a 35 mg Immediate-Release Administered Weekly for 13 Weeks to Postmenopausal Women [NCT00577720]	Phase 2	181 participants (Actual)	Interventional	2006-07-31	Completed
A Crossover Study to Assess the Bioequivalence of the Phase III and Commercial Risedronate 35 mg Delayed Release Formulations. [NCT00846196]	Phase 1	538 participants (Actual)	Interventional	2009-01-31	Completed
Active-controlled, Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density [NCT00577837]	Phase 2	370 participants (Actual)	Interventional	2004-04-30	Completed
Risedronate for Prevention of Osteoporosis After Spinal Cord Injury [NCT00150696]	Phase 3	38 participants	Interventional	2000-02-29	Completed
Benet 75 mg Tablets Special Drug Use Surveillance: Long-term Use (12-month Treatment Survey) [NCT02089997]		3,304 participants (Actual)	Observational	2013-05-27	Completed
Treatment of Childhood Cancer Therapy-induced Osteopenia in Growth Hormone Deficient Adult Survivors: Does Bisphosphonate Treatment Improve Bone Mineral Density? [NCT00145704]		6 participants (Actual)	Interventional	2002-06-30	Terminated(stopped due to due to low enrollment, participants are no longer being examined or treated)
A Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Noninferiority Study Comparing 75mg Risedronate Dosed on 2 Consecutive Days Monthly With 5mg Daily Risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed Over 24 [NCT00358176]	Phase 3	1,231 participants (Actual)	Interventional	2004-07-31	Completed
A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily [NCT00453492]	Phase 4	246 participants	Interventional	2004-01-31	Completed
A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 24 Month, Monocenter Study Comparing Weekly Oral Risedronate 35 mg and Placebo [NCT00345644]	Phase 3	156 participants (Anticipated)	Interventional	2006-03-31	Completed
The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer [NCT00354302]	Phase 3	497 participants (Actual)	Interventional	2006-04-24	Completed
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children [NCT00106028]	Phase 3	143 participants (Actual)	Interventional	2004-11-30	Completed
Local (Brazil) Study, Multicenter, Opened, Comparative, Randomized, With Parallel Groups, Phase IV, in Post Menopausal Woman With Colles' Fracture of the Risedronate Sodium Usage in the Consolidation and in the Callus of the Colles'Fracture. [NCT00460733]	Phase 4	141 participants (Actual)	Interventional	2007-03-31	Completed
[NCT00372372]	Phase 4	120 participants	Interventional	2004-01-31	Completed
A Multicentre Phase III/IV Study, of the Effects of Risedronate Sodium (ACTONEL™, 35mg/Week, Oral) on Bone, in Postmenopausal Women, With Hormone-receptor-positive Early Breast Cancer, Treated With Anastrozole (ARIMIDEX™, 1mg/Day Oral) With Risk of Fragil [NCT00082277]	Phase 4	237 participants (Actual)	Interventional	2004-04-30	Completed
Effects of Bisphosphonates on OI-Related Hearing Loss: A Pilot Study [NCT04152551]	Phase 4	100 participants (Anticipated)	Interventional	2019-11-02	Recruiting
A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women [NCT00402441]	Phase 4	260 participants (Actual)	Interventional	2002-09-30	Completed
a Six Month, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group Study to Estimate the Pharmacodynamic Response of Two Risedronate Regimens Compared With 5mg Daily : 150mg Monthly Dose for Six Months and 15mg Daily for Thirty Days Fol [NCT00351091]	Phase 2	150 participants (Actual)	Interventional	2002-11-30	Completed
A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal) [NCT00353080]	Phase 3	171 participants (Actual)	Interventional	2002-12-31	Completed
The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study) [NCT00118508]		87 participants (Actual)	Interventional	2003-05-31	Completed
A 1-year, Risedronate-free, Multicenter, Outpatient, Phase IIIb Extension Study to Assess Bone Turnover Recovery in Women With Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, and RVE1998080 (no NCT Study Numb [NCT01249261]	Phase 3	61 participants (Actual)	Interventional	2001-10-31	Completed
Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients [NCT00136058]	Phase 3	250 participants	Interventional	2002-01-31	Completed
Risedronate for Treatment of Sublesional Osteoporosis After Spinal Cord Injury [NCT00138866]	Phase 3	46 participants (Anticipated)	Interventional	2004-11-30	Completed
Antiepileptic Drugs and Osteoporotic Prevention Trial [NCT00869622]	Phase 4	80 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy [NCT00919711]	Phase 3	870 participants (Actual)	Interventional	2009-09-01	Completed
Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study [NCT00043069]	Phase 3	71 participants (Actual)	Interventional	2002-11-30	Completed
A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma [NCT00054418]	Phase 3	216 participants (Actual)	Interventional	2003-03-31	Completed
The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy [NCT00485953]	Phase 4	109 participants (Actual)	Interventional	2007-09-30	Completed
For 4 Months, the Multi Center, Double Blinded, Randomized, Active Controlled, Comparative Clinical Study to Assess the Efficacy and the Safety to Improvement Effect of Vit.D of Risenex Plus M Tablet in Patients With In Post-menopausal Women Osteoporosis [NCT01806792]	Phase 3	150 participants (Actual)	Interventional	2009-11-30	Completed
Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide [NCT00130403]	Phase 4	290 participants (Actual)	Interventional	2004-03-31	Completed
Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women [NCT02186600]	Phase 3	276 participants (Actual)	Interventional	2015-02-01	Completed
A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO) [NCT00247273]	Phase 3	1,294 participants (Actual)	Interventional	2005-10-31	Completed
The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men [NCT00859027]	Phase 4	50 participants (Actual)	Interventional	2003-01-31	Completed
A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate. [NCT00268632]	Phase 3	0 participants	Interventional	1999-08-31	Completed
Metabolism and Bone Health [NCT00244907]	Phase 1	23 participants (Actual)	Interventional	2006-01-31	Completed
A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women [NCT00324714]	Phase 3	0 participants (Actual)	Interventional	2003-02-28	Withdrawn
A Randomized Clinical Trial of Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT [NCT03861091]	Phase 2	84 participants (Actual)	Interventional	2019-07-12	Completed
Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture [NCT01950169]		79 participants (Actual)	Interventional	2004-12-31	Completed
IGF-1 and Bone Loss in Women With Anorexia Nervosa [NCT01406444]		148 participants (Actual)	Interventional	2011-10-31	Completed
For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis [NCT01675297]	Phase 4	1,053 participants (Actual)	Interventional	2011-07-04	Completed
Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis [NCT01611571]	Phase 3	31 participants (Actual)	Interventional	2003-12-31	Completed
Replication of the VERO Osteoporosis Trial in Healthcare Claims Data [NCT04879420]		12,757 participants (Actual)	Observational	2020-10-29	Completed
IGF-1 and Bone Loss in Women Anorexia Nervosa [NCT00089843]	Phase 2/Phase 3	77 participants (Actual)	Interventional	2003-06-30	Completed
Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients [NCT05346419]		33 participants (Actual)	Interventional	2021-07-01	Completed
Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis? [NCT00221299]	Phase 4	60 participants (Actual)	Interventional	2005-09-30	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41 [NCT00216060]	Phase 3	63 participants (Actual)	Interventional	2003-10-31	Terminated(stopped due to Terminated due to low accrual)
A Randomized, Single-blind, Placebo-controlled, Multicentre Study to Evaluate the Effect of Risedronate and Placebo on Bone Mineral Density in Men Undergoing Androgen Deprivation Therapy With Leuprolide Acetate [NCT00426777]	Phase 3	160 participants (Actual)	Interventional	2007-01-31	Completed
36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Benet 75 mg Tablets [NCT02106442]		579 participants (Actual)	Observational	2013-05-13	Completed
A Phase 2/3, Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Once-monthly Oral Administration of NE-58095DR Tablet (25 mg or 37.5 mg) Versus Once-daily Oral Administration of NE-58095IR Tablet [NCT02063854]	Phase 2/Phase 3	871 participants (Actual)	Interventional	2014-02-28	Completed
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery [NCT04922333]	Phase 3	200 participants (Anticipated)	Interventional	2023-03-28	Recruiting
Sodium Risedronate 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance - [NCT02106455]		315 participants (Actual)	Observational	2008-08-01	Completed
Prevention of Osteoporosis in Breast Cancer Survivors [NCT00567606]		249 participants (Actual)	Interventional	2002-04-01	Completed
Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures [NCT01709110]	Phase 4	1,366 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00051636 (11) [back to overview]	Change in Pain Interference Score
NCT00051636 (11) [back to overview]	Change in Pain Severity Score
NCT00051636 (11) [back to overview]	Number of Participants With a Disease Relapse During the Extended Observation Period
NCT00051636 (11) [back to overview]	Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period
NCT00051636 (11) [back to overview]	Number of Participants With a Partial Disease Relapse During the Extended Observation Period
NCT00051636 (11) [back to overview]	Number of Patients Who Achieve Therapeutic Response at 6 Months.
NCT00051636 (11) [back to overview]	Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28 Relative to Baseline
NCT00051636 (11) [back to overview]	Relative Change in Serum Alkaline Phosphatase (SAP) in Units Per Liter (U/L) at Day 28
NCT00051636 (11) [back to overview]	Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10
NCT00051636 (11) [back to overview]	Relative Change in Urine Alpha C-telopeptide (α-CTx) in ug/mmol at Day 10
NCT00051636 (11) [back to overview]	Time to First Therapeutic Response
NCT00089843 (2) [back to overview]	Bone Mineral Density
NCT00089843 (2) [back to overview]	Markers of Bone Metabolism
NCT00103740 (11) [back to overview]	Number of Patients Who Had Therapeutic Response at 6 Months
NCT00103740 (11) [back to overview]	Relative Change in Serum Alkaline Phosphatase in U/L at Day 28
NCT00103740 (11) [back to overview]	Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10
NCT00103740 (11) [back to overview]	Relative Change in Urine α-CTx in ug/mmol at Day 10
NCT00103740 (11) [back to overview]	Time to First Therapeutic Response
NCT00103740 (11) [back to overview]	Change in Pain Interference at Day 182
NCT00103740 (11) [back to overview]	Change in Pain Severity at Day 182
NCT00103740 (11) [back to overview]	Number of Participants With a Disease Relapse During the Extended Observation Period
NCT00103740 (11) [back to overview]	Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period
NCT00103740 (11) [back to overview]	Number of Participants With a Partial Disease Relapse During the Extended Observation Period
NCT00103740 (11) [back to overview]	Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 24, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 12, ITT Population
NCT00106028 (44) [back to overview]	Lumbar Spine Z-score - Percent Change From Baseline to Month 36, ITT Population
NCT00106028 (44) [back to overview]	Lumbar Spine Z-score - Percent Change From Baseline to Month 24, ITT Population
NCT00106028 (44) [back to overview]	Lumbar Spine Z-score - Percent Change From Baseline to Month 12, ITT Population
NCT00106028 (44) [back to overview]	Bone Age (Years), Change From Baseline to Month 36, ITT Population
NCT00106028 (44) [back to overview]	Bone Age (Years), Change From Baseline to Month 24, ITT Population
NCT00106028 (44) [back to overview]	Bone Age (Years), Change From Baseline to Month 12, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population
NCT00106028 (44) [back to overview]	Annualized Growth Velocity - Change From Baseline to Month 36, ITT Population
NCT00106028 (44) [back to overview]	Annualized Growth Velocity - Change From Baseline to Month 12, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 24, ITT Population
NCT00106028 (44) [back to overview]	Number of Clinical Fractures, Month 12, ITT Population
NCT00106028 (44) [back to overview]	New Morphometric Vertebral Fracture at Month 36, ITT Population
NCT00106028 (44) [back to overview]	New Morphometric Vertebral Fracture at Month 12, ITT Population
NCT00106028 (44) [back to overview]	Incidence New Vertebral Fractures by SQ Score, Patients Aged 10-15 Years, Month 12, ITT Population
NCT00106028 (44) [back to overview]	Incidence New Vertebral Fractures by SQ (Semi-Quantitative) Score, Patients Aged 4-9 Years, Month 12, ITT Population
NCT00106028 (44) [back to overview]	Categorization by Number of New Morphometric Vertebral Fracture at Month 36, ITT
NCT00106028 (44) [back to overview]	Categorization by Number of New Morphometric Vertebral Fracture at Month 12, ITT
NCT00106028 (44) [back to overview]	Wong-Baker FACES Pain Rating Scale - Change From Baseline to Month 12, ITT Population
NCT00106028 (44) [back to overview]	Urine NTX/Cr - Percent Change From Baseline at Month 36, ITT Population
NCT00106028 (44) [back to overview]	Urine NTX/Cr - Percent Change From Baseline at Month 24, ITT Population
NCT00106028 (44) [back to overview]	Urine NTX/Cr - Percent Change From Baseline at Month 12, ITT Population
NCT00106028 (44) [back to overview]	Total Body Z-score- Percent Change From Baseline to Month 36, ITT Population
NCT00106028 (44) [back to overview]	Total Body Z-score- Percent Change From Baseline to Month 24, ITT Population
NCT00106028 (44) [back to overview]	Total Body Z-score- Percent Change From Baseline to Month 12, ITT Population
NCT00106028 (44) [back to overview]	Serum BAP - Percent Change From Baseline to Month 36, ITT Population
NCT00106028 (44) [back to overview]	Serum BAP - Percent Change From Baseline to Month 24, ITT Population
NCT00106028 (44) [back to overview]	Serum BAP - Percent Change From Baseline to Month 12, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 36, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body Bone Area Month 36, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body Bone Area Month 24, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body Bone Area Month 12, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body BMD at Month 36, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body BMD at Month 24, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body BMD at Month 12, ITT Population
NCT00106028 (44) [back to overview]	Probability of Fracture in 12 Months (Kaplan-Meier Cumulative Incidence), ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body BMC at Month 36, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body BMC at Month 24, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Total Body BMC at Month 12, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Area at Month 36, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Area at Month 24, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Area at Month 12, ITT Population
NCT00106028 (44) [back to overview]	Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 36, ITT Population
NCT00216060 (7) [back to overview]	Bone Turnover Marker Changes-- Serum BAP
NCT00216060 (7) [back to overview]	Bone Turnover Marker Changes-- Urine N-telopeptide (NTX) Median
NCT00216060 (7) [back to overview]	Three- Year Survival Rate
NCT00216060 (7) [back to overview]	Bone Turnover Marker Changes-- Serum Osteocalcin (OC)
NCT00216060 (7) [back to overview]	Numbers of SRE or Death Occurred Cumulatively
NCT00216060 (7) [back to overview]	Rate of Patients Archiving a PSA (Prostate Specific Antigen) Nadir < 0.2 ng/mL
NCT00216060 (7) [back to overview]	Bone Turnover Marker Changes -- Urine Total Deoxypyridinoline (DPD)
NCT00221299 (1) [back to overview]	Bone Mineral Density (BMD): Examine the Pattern and Effect of BMD Changes at Hip and Spine Measured by DXA Every 6 Months.
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Serum BAP at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Lumbar Spine BMD at Month 24-Endpoint, Endpoint Population (Month 24)
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population
NCT00247273 (20) [back to overview]	Number of Participants With New Vertebral Fracture at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Number of Participants With New Vertebral Fracture at Month 12, ITT Population
NCT00247273 (20) [back to overview]	Change From Baseline in Urine Type-1 Collagen Cross-linked-N-telopeptide Corrected for Creatinine Clearance (NTX/Cr) at Month 6, ITT Population
NCT00247273 (20) [back to overview]	Change From Baseline in Urine NTX/Cr at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Serum CTX at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Serum BAP at Month 6, ITT Population
NCT00247273 (20) [back to overview]	Change From Baseline in Serum Type-1 Collagen Cross-linked C-telopeptide (CTX) at Month 6, ITT Population
NCT00247273 (20) [back to overview]	Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population
NCT00247273 (20) [back to overview]	Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Change From Baseline in Serum BAP at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Change From Baseline in Serum CTX at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Change From Baseline in Serum Bone-specific Alkaline Phosphatase (BAP) at Month 6, ITT Population
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Urine NTX/Cr at Month 6, ITT Population
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Urine NTX/Cr at Month 24, ITT Population
NCT00247273 (20) [back to overview]	Percent Change From Baseline in Serum CTX at Month 6, ITT Population
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Percent Bone Volume (BV/TV)
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Osteoid Volume (OV)
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Bone Formation Rate
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Mineralized Bone Volume (MdV)
NCT00266708 (18) [back to overview]	Bone Mineral Density of Spine at 12 Months
NCT00266708 (18) [back to overview]	Bone Mineral Density of Spine at 6 Months
NCT00266708 (18) [back to overview]	Bone Mineral Density of the Hip at 12 Months
NCT00266708 (18) [back to overview]	Bone Mineral Density of Forearm at 6 Months
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Percent Eroded Surface Relative to Bone Surface (ES/BS)
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Percent Mineralized Bone Volume (MdV/BV)
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Percent Osteoblasts Relative to Bone Surface (OB/BS)
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Percent Osteoclasts Relative to Bone Surface (OC/BS)
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Percent Osteoid Surface Relative to Bone Surface (OS/BS)
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Percent Osteoid Volume Relative to Bone Volume(OV/BV)
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Percent Osteoid Volume Relative to Tissue Volume (OV/TV)
NCT00266708 (18) [back to overview]	Bone Mineral Density of the Hip at 6 Months
NCT00266708 (18) [back to overview]	Bone Histomorphometry - Trabecular Thickness (TbTh)
NCT00266708 (18) [back to overview]	Bone Mineral Density of Forearm at 12 Months
NCT00343252 (21) [back to overview]	Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 12-Month Endpoint
NCT00343252 (21) [back to overview]	Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 18-Month Endpoint
NCT00343252 (21) [back to overview]	Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint
NCT00343252 (21) [back to overview]	Number of Participants With Adverse Events (Safety) During 12 Months
NCT00343252 (21) [back to overview]	Number of Participants With Adverse Events (Safety) During 18 Months
NCT00343252 (21) [back to overview]	Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 12 Months
NCT00343252 (21) [back to overview]	Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 6 Months
NCT00343252 (21) [back to overview]	Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 6-Month Endpoint
NCT00343252 (21) [back to overview]	Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 12 Months
NCT00343252 (21) [back to overview]	Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 6 Months
NCT00343252 (21) [back to overview]	Change From Baseline to 12-Month Endpoint in the Roland-Morris Disability Questionnaire.
NCT00343252 (21) [back to overview]	Change From Baseline to 12-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)
NCT00343252 (21) [back to overview]	Change From Baseline to 18-Month Endpoint in European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)
NCT00343252 (21) [back to overview]	Change From Baseline to 18-Month Endpoint in the Roland-Morris Disability Questionnaire.
NCT00343252 (21) [back to overview]	Change From Baseline to 3-Month Endpoint in the Roland-Morris Disability Questionnaire.
NCT00343252 (21) [back to overview]	Change From Baseline to 6-Month Endpoint in the Roland-Morris Disability Questionnaire.
NCT00343252 (21) [back to overview]	Change From Baseline to 6-Month Endpoint, European Foundation for Osteoporosis Quality of Life Instrument (QUALEFFO)
NCT00343252 (21) [back to overview]	Number of Participants With Time to First Occurrence of at Least 30% Reduction in 24-Hour Worst Back Pain up to 18 Months
NCT00343252 (21) [back to overview]	Number of Participants With Time to First Occurrence of at Least a 30% Reduction in 24-Hour Average Back Pain up to 18 Months
NCT00343252 (21) [back to overview]	Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 12-Month Endpoint
NCT00343252 (21) [back to overview]	Number of Participants Responding With at Least a 30% Reduction in 24-Hour Average Back Pain Severity at the 18-Month Endpoint
NCT00365456 (1) [back to overview]	Change in Lumbar Spine BMD From Start of Trial Period III Until End of Trial Period III.
NCT00377234 (3) [back to overview]	Intensity of Upper Gastrointestinal (GI) Symptoms
NCT00377234 (3) [back to overview]	Percentage of Participants Who Preferred Ibandronate Monthly Dosing to Risedronate Weekly Dosing
NCT00377234 (3) [back to overview]	Percentage of Participants Who Found Once-monthly Ibandronate to be More Convenient Than Once-weekly Risedronate
NCT00386360 (14) [back to overview]	Total Proximal Femur BMD (Bone Mineral Density), Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Procollagen Type 1 N-Propeptide, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Lumbar Spine BMD, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Height, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Average Bone Density at Distal Tibia, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Greater Trochanter BMD, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Femoral Neck BMD, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Compact Bone Density at Distal Tibia, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Compact Bone Density at Distal Radius, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Average Bone Density at Distal Radius, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Type I Collagen C-Telopeptides, Serum, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Trabecular Bone Volume to Tissue Volume at Distal Radius, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Trabecular Bone Density at Distal Tibia, Percent Change From Baseline to Month 12
NCT00386360 (14) [back to overview]	Trabecular Bone Density at Distal Radius, Percent Change From Baseline to Month 12
NCT00452439 (2) [back to overview]	Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at the 6 Months
NCT00452439 (2) [back to overview]	Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at 12 Months
NCT00485953 (3) [back to overview]	Markers of Bone Resorption and Bone Formation
NCT00485953 (3) [back to overview]	BMD by DXA at the Femoral Neck and Total Hip
NCT00485953 (3) [back to overview]	BMD of Spine by DXA
NCT00503399 (9) [back to overview]	Change From Baseline in Areal Bone Mineral Density (BMD) at Lumbar Spine, Femoral Neck, and Total Hip at 18 Months
NCT00503399 (9) [back to overview]	Change From Baseline in Axial Compression by Finite Element Analysis in the 12th Thoracic Vertebra (T12) at 6 Months and 18 Months: Stiffness and Strength
NCT00503399 (9) [back to overview]	Change From Baseline in High Resolution Quantitative Computerized Technology (HR-QCT) of Integral and Trabecular Bone Mineral Density (BMD) of the 12th Thoracic Vertebra (T12) at 6 Months and 18 Months
NCT00503399 (9) [back to overview]	Change From Baseline in Serum Aminoterminal Propeptide of Type I Procollagen (P1NP) at 3 Months, 6 Months, and 18 Months
NCT00503399 (9) [back to overview]	Change From Baseline in Serum Type I Collagen Degradation Fragments (β-CTx) at 3 Months, 6 Months, and 18 Months
NCT00503399 (9) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00503399 (9) [back to overview]	Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Technology (QCT) at 6 Months
NCT00503399 (9) [back to overview]	Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Tomography (QCT) at 18 Months
NCT00503399 (9) [back to overview]	Change From Baseline in Anterior Bending and Axial Torsion by Finite Element Analysis in the 12th Thoracic Vertebra (T12) at 6 Months and 18 Months: Stiffness and Strength
NCT00541658 (51) [back to overview]	Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52, ITT Population
NCT00541658 (51) [back to overview]	Number of Patients With No New Fractured Vertebra, Week 104 / Endpoint
NCT00541658 (51) [back to overview]	Number of Patients With No New Fractured Vertebra, Week 52
NCT00541658 (51) [back to overview]	Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 26, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Total Proximal Femur BMD, Week 52 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Total Proximal Femur BMD, Week 104, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Total Proximal Femur BMD, Week 104 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 13, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 26, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Week 52 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Lumbar Spine BMD, Week 52, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Lumbar Spine BMD, Week 26, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Lumbar Spine BMD for Combined 35 mg Delayed-Release Weekly Treatment Group, Week 52 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Lumbar Spine BMD at Week 104, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, Week 104, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Lumbar Spine BMD at Week 104 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Total Proximal Femur BMD, Week 52, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Total Proximal Femur BMD, Week 26, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104, ITT Population
NCT00541658 (51) [back to overview]	Number of Patients With No New Fractured Vertebra, Week 52 / Endpoint
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, Week 52, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 26, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 13, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Greater Trochanter BMD, Week 52, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Greater Trochanter BMD, Week 52 / Endpoint
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Greater Trochanter BMD, Week 104, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Greater Trochanter BMD, Week 104 / Endpoint
NCT00541658 (51) [back to overview]	Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD) at Week 104, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, Week 52 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, Week 26, ITT Population
NCT00541658 (51) [back to overview]	Number of Patients With at Least One New Fractured Vertebra, Week 104 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Number of Patients With at Least One New Fractured Vertebra, Week 104, ITT Population
NCT00541658 (51) [back to overview]	Number of Patients With at Least One New Fractured Vertebra, Week 52
NCT00541658 (51) [back to overview]	Number of Patients With at Least One New Fractured Vertebra, Week 52 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Greater Trochanter BMD, Week 26, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, Week 104 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD), Week 52, ITT Population
NCT00541658 (51) [back to overview]	Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD) at Week 52 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Number of Patients With No New Fractured Vertebra, Week 104
NCT00541658 (51) [back to overview]	Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD) at Week 104 / Endpoint, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Urine Type-I Collagen N-telopeptide/ Creatinine (NTX/Cr), Week 13, ITT Population
NCT00541658 (51) [back to overview]	Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52 / Endpoint, ITT Population
NCT00577720 (3) [back to overview]	Percent Change in Urine NTX/Cr (Urine Type I Collagen Cross-linked N-telopeptide Corrected for Creatinine Clearance), ITT Population
NCT00577720 (3) [back to overview]	Percent Change in Serum BAP (Bone-specific Alkaline Phosphatase), ITT Population
NCT00577720 (3) [back to overview]	Percent Change in Serum CTX (Type I Collagen C-telopeptide), ITT (Intent to Treat) Population
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, Month 12, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, Month 24, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, Month 6, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Femoral Trochanter BMD, 24 Months/Endpoint, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Femoral Trochanter BMD, Month 12, ITT Population.
NCT00619957 (37) [back to overview]	Change From Baseline in Body Height, 24 Months/Endpoint, ITT Population.
NCT00619957 (37) [back to overview]	Change From Baseline in Body Height, Month 12, ITT Population.
NCT00619957 (37) [back to overview]	Cumulative Incidence of Fractures, 12 Months, ITT Population
NCT00619957 (37) [back to overview]	Cumulative Incidence of Fractures, 24 Months, ITT Population
NCT00619957 (37) [back to overview]	Percent Change From Baseline in BAP (Bone-specific Alkaline Phosphatase), Month 3, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in BAP, 24 Months/Endpoint, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in BAP, Month 12, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in BAP, Month 24, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in BAP, Month 6, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in CTx (Type I Collagen C-telopeptide), Month 3, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in CTx, 24 Months/Endpoint, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in CTx, Month 12, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in CTx, Month 6, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), 24 Months/Endpoint, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in CTx, Month 24, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Femoral Trochanter BMD, Month 24, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Femoral Trochanter BMD, Month 6, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Lumbar Spine BMD, Month 12, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Lumbar Spine BMD, Month 24, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in NTx/Cr (Type I Collagen N-telopeptide/Creatinine), Month 3, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in NTx/Cr, 24 Months/Endpoint, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in NTx/Cr, Month 12, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in NTx/Cr, Month 24, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in NTx/Cr, Month 6, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Total Proximal Femur BMD, Month 24, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Total Proximal Femur BMD, Month 6, ITT Population.
NCT00619957 (37) [back to overview]	Percent of Responders Lumbar Spine BMD, Month 24, ITT Population
NCT00619957 (37) [back to overview]	Change From Baseline in Body Height, Month 24, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Total Proximal Femur BMD, 24 Months/Endpoint, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Lumbar Spine BMD, Month 6, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Total Proximal Femur BMD, Month 12, ITT Population.
NCT00619957 (37) [back to overview]	Percent Change From Baseline in Femoral Neck BMD, 24 Months/Endpoint, ITT Population.
NCT00859027 (2) [back to overview]	Percent Change in Bone Mineral Density
NCT00859027 (2) [back to overview]	Percent Change of Bone Turnover Markers
NCT00869622 (2) [back to overview]	Vertebral Fractures
NCT00869622 (2) [back to overview]	Changes in Bone Mineral Density
NCT00887354 (7) [back to overview]	"Timed Up and Go Test"
NCT00887354 (7) [back to overview]	Percentage of Participants Reporting Hip Pain in Modification of the Charnley's Pain Scale
NCT00887354 (7) [back to overview]	Visual Analog Scale (VAS)
NCT00887354 (7) [back to overview]	Change in Lumbar Spine Areal Bone Mineral Density
NCT00887354 (7) [back to overview]	Change in Areal Bone Mineral Density Measured at the Femoral Neck and Total Hip of the Non-Fractured Limb
NCT00887354 (7) [back to overview]	Change From Baseline in Physical Component Summary of the Short Form-36 (SF-36) Questionnaire
NCT00887354 (7) [back to overview]	Change in Lumbar Spine Areal Bone Mineral Density (BMD)
NCT00919711 (4) [back to overview]	Total Hip BMD Percent Change From Baseline at Month 12
NCT00919711 (4) [back to overview]	Serum CTX Percent Change From Baseline at Month 1
NCT00919711 (4) [back to overview]	Lumbar Spine BMD Percent Change From Baseline at Month 12
NCT00919711 (4) [back to overview]	Femoral Neck BMD Percent Change From Baseline at Month 12
NCT01077817 (2) [back to overview]	Percentage of Participants With Exposure to Study Drugs (Case-Cohort Analysis)
NCT01077817 (2) [back to overview]	Number of Cases of Esophageal Cancer Per 100,000 Woman-Years (Intent-to-Treat Analysis)
NCT01249261 (12) [back to overview]	Mean Percent Change in Femoral Trochanter BMD From Core Study Baseline, Month 12, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Total Proximal Femur BMD From Core Study Baseline, Month 12, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Femoral Neck BMD From Core Study Baseline, Month 12/Endpoint, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Femoral Neck BMD From Core Study Baseline, Month 12, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Total Proximal Femur BMD From Core Study Baseline, Month 6, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Total Proximal Femur BMD From Core Study Baseline, Month 12/Endpoint, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Femoral Neck BMD From Core Study Baseline, Month 6, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Core Study Baseline, Month 6, Intention to Treat (ITT) Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Lumbar Spine BMD From Core Study Baseline, Month 12/Endpoint, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Lumbar Spine BMD From Core Study Baseline, Month 12, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Femoral Trochanter BMD From Core Study Baseline, Month 6, ITT Population
NCT01249261 (12) [back to overview]	Mean Percent Change in Femoral Trochanter BMD From Core Study Baseline, Month 12/Endpoint, ITT Population
NCT01406444 (2) [back to overview]	Lateral Spine Bone Mineral Density by DXA
NCT01406444 (2) [back to overview]	Postero-anterior Spine Bone Mineral Density by DXA
NCT01611571 (5) [back to overview]	Change in FN BMD at 18 Months
NCT01611571 (5) [back to overview]	Change in Hip Bone Density
NCT01611571 (5) [back to overview]	Change in Spine Bone Density
NCT01611571 (5) [back to overview]	Change in Forearm Bone Density
NCT01611571 (5) [back to overview]	New Morphometric Vertebral Fractures
NCT01675297 (3) [back to overview]	The Change of Bone Mineral Density (BMD) Value
NCT01675297 (3) [back to overview]	PTH(Parathyroid Hormone Value)
NCT01675297 (3) [back to overview]	The Change of 25OHD(25-hydroxyvitamin D)
NCT01709110 (12) [back to overview]	Change From Baseline to 24 Months Endpoint in the European Quality of Life Questionnaire [EQ-5D-5L] (US)
NCT01709110 (12) [back to overview]	Change From Baseline to 24 Months Endpoint in the European Quality of Life Questionnaire [EQ-5D-5L] (UK)
NCT01709110 (12) [back to overview]	Change From Baseline to 24 Months Endpoint in Height
NCT01709110 (12) [back to overview]	Change From Baseline to 24 Months Endpoint in Back Pain Using an 11-point Numerical Pain Rating Scale
NCT01709110 (12) [back to overview]	Proportion of Participants With Pooled New and Worsening Vertebral Fractures
NCT01709110 (12) [back to overview]	Proportion of Participants With Pooled Fragility and Traumatic Non-Vertebral Fractures
NCT01709110 (12) [back to overview]	Proportion of Participants With Pooled Clinical Vertebral and Non-Vertebral Fragility Fractures
NCT01709110 (12) [back to overview]	Proportion of Participants With Non-Vertebral Fragility Fractures
NCT01709110 (12) [back to overview]	Proportion of Participants With New Vertebral Fractures
NCT01709110 (12) [back to overview]	Proportion of Participants With New Multiple (2 or More) Vertebral Fractures
NCT01709110 (12) [back to overview]	Proportion of Participants With Major Non-Vertebral Fragility Fractures
NCT01709110 (12) [back to overview]	Proportion of Participants With New Moderate and/or Severe Vertebral Fractures
NCT01950169 (4) [back to overview]	Body Composition, Including Fat Mass at Baseline, 6 and 12 Months After Hip Fracture.
NCT01950169 (4) [back to overview]	Body Composition, Including Lean Mass at Baseline, 6 and 12 Months After Hip Fracture.
NCT01950169 (4) [back to overview]	Total Body Mineral Density (BMD) at Baseline, 6 and 12 Months After Hip Fracture.
NCT01950169 (4) [back to overview]	Total Hip Bone Mineral Density (BMD) at Baseline, 6 and 12 Months After Hip Fracture.
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Bone Turnover Marker Serum Creatinine (CTX) at Each Visit
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Bone Turnover Marker Serum Procollagen 1 N-terminal Peptide (P1NP) at Each Visit
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Bone Turnover Marker Urine Type 1 Collagen Cross-linked N-telopeptide (NTX) at Each Visit
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Femur (Femoral Neck) BMD Measured by DXA at Each Visit
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Femur (Total Proximal Femur) BMD Measured by DXA at Each Visit
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Femur (Trochanter) BMD Measured by DXA at Each Visit
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Mean Lumbar Spine (L2-L4) BMD Measured by DXA at Each Visit
NCT02063854 (11) [back to overview]	Percentage of Participants With New Non-traumatic Vertebral Fractures (Including the Worsening of Pre-existing Fractures)
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Bone Turnover Marker Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Each Visit
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry (DXA) at End of Study
NCT02063854 (11) [back to overview]	Percent Change From Baseline in Bone Turnover Marker Serum Bone-type Alkaline Phosphatase (BAP) at Each Visit
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) at Final Assessment
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Final Assessment
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Serum Procollagen 1 N-terminal Peptide (P1NP) at Final Assessment
NCT02089997 (12) [back to overview]	Change From Baseline in Height
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Radius BMD at Final Assessment
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Femur (Total Proximal Femur) BMD at Final Assessment
NCT02089997 (12) [back to overview]	Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)
NCT02089997 (12) [back to overview]	Number of Participants Who Had Lumbar Backache at Final Assessment
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Serum Bone-type Alkaline Phosphatase (BAP) at Final Assessment
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Serum Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Urinary Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment
NCT02089997 (12) [back to overview]	Percent Change From Baseline in Femur (Neck Region) BMD at Final Assessment
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Serum Bone-type Alkaline Phosphatase (BAP) at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Femur Neck BMD at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Serum Procollagen 1 N-terminal Peptide (P1NP) at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Serum Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Bone Metabolism Markers Urinary Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Number of Participants Who Had One or More Adverse Drug Reactions
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Radius BMD at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Percent Change From Baseline in Total Proximal Femur BMD at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Cumulative Percentage of Participants With Femur Fractures
NCT02106442 (15) [back to overview]	Cumulative Percentage of Participants With New or Worsening Vertebral Body Fractures
NCT02106442 (15) [back to overview]	Cumulative Percentage of Participants With Non-Vertebral Body Fractures
NCT02106442 (15) [back to overview]	Number of Participants Who Had Lumbar Backache at Final Assessment (up to Month 36)
NCT02106442 (15) [back to overview]	Change From Baseline in Height at Final Assessment (up to Month 36)
NCT02106455 (7) [back to overview]	Percentage of Changes From Baseline in Urinary Deoxypyridinoline (Urinary DPD) Level at Final Assessment Point
NCT02106455 (7) [back to overview]	Percentage of Changes From Baseline in Urinary Type 1 Collagen Cross-Linked N-telopeptide (Urinary NTX) Level at Final Assessment Point
NCT02106455 (7) [back to overview]	Percentage of Participants Stratified by Treatment Compliance (Medicine Adherence) During Treatment Period
NCT02106455 (7) [back to overview]	Percentage of Changes From Baseline in Excess Serum Alkaline Phosphatase (ALP) Level at Final Assessment Point
NCT02106455 (7) [back to overview]	Percentage of Changes From Baseline in Serum ALP Level at Final Assessment Point
NCT02106455 (7) [back to overview]	Percentage of Changes From Baseline in Serum Bone Alkaline Phosphatase (Serum BAP) Level at Final Assessment Point
NCT02106455 (7) [back to overview]	Percentage of Participants Who Had One or More Adverse Drug Reactions
NCT02186600 (3) [back to overview]	Change in Serum Measures of Bone Resorption (Serum NTx) Based on Randomization to Control, Risedronate, or Exercise Group.
NCT02186600 (3) [back to overview]	Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group.
NCT02186600 (3) [back to overview]	Change in Bone Mineral Density (BMD) at the Spine (L1-L4) Based on Randomization to Control, Risedronate, or Exercise Group.
NCT03411902 (7) [back to overview]	Number of Enrolled Participants That Completed All 24 Week Procedures
NCT03411902 (7) [back to overview]	Fat Pounds
NCT03411902 (7) [back to overview]	Total Change in Lumbar Spine Density
NCT03411902 (7) [back to overview]	Lean Pounds
NCT03411902 (7) [back to overview]	Total Change in Femoral Neck Hip Density
NCT03411902 (7) [back to overview]	Trabecular Bone Score (TBS)
NCT03411902 (7) [back to overview]	Duel-energy X-ray Absorptiometry (DXA)-Acquired Measure for Ultradistal Radius (or UD Radius) Density
NCT03861091 (5) [back to overview]	Urine Concentration at 4 Time Points
NCT03861091 (5) [back to overview]	4 Time Points Assessing Change in Mean Cortical Thickness of Bones
NCT03861091 (5) [back to overview]	Number of Participants With Rib and Vertebral Fracture
NCT03861091 (5) [back to overview]	Number of Participants With Chest Wall Pain
NCT03861091 (5) [back to overview]	Changes in Mean Cortical Thickness

Change in Pain Interference Score

Change in pain interference score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain. (NCT00051636)
Timeframe: Baseline and day 182

Intervention	Units on a scale (Mean)
Zoledronic Acid and Placebo to Risedronate	-0.2
Risedronate and Placebo to Zoledronic Acid	0.1

Intervention	Units on a scale (Mean)
Zoledronic Acid and Placebo to Risedronate	-0.5
Risedronate and Placebo to Zoledronic Acid	-0.7

Intervention	percent change (Mean)
Zoledronic Acid and Placebo to Risedronate	-48.8
Risedronate and Placebo to Zoledronic Acid	-28.4

Intervention	percent change (Mean)
Zoledronic Acid and Placebo to Risedronate	-85.4
Risedronate and Placebo to Zoledronic Acid	-36.7

Intervention	Percent change (Mean)
Zoledronic Acid and Placebo to Risedronate	-90.3
Risedronate and Placebo to Zoledronic Acid	-29.9

Intervention	percent change (Mean)
Zoledronic Acid and Placebo to Risedronate	-49.1
Risedronate and Placebo to Zoledronic Acid	-24.3

Intervention	percent change (Mean)
Zoledronic Acid and Placebo to Risedronate	-74.2
Risedronate and Placebo to Zoledronic Acid	-40.1

Intervention	percent change (Mean)
Zoledronic Acid and Placebo to Risedronate	-87.5
Risedronate and Placebo to Zoledronic Acid	-28.7

Intervention	Participants (Number)
	Number of Fractures	Number of Patients with Fractures	Number of Vertebral Fractures	Number Patients with Vertebral Fractures	Number of Non-Vertebral Fractures	Number Patients with Non-Vertebral Fractures	Number Long-Bone Non-Vertebral Fractures	Number Patients Long-Bone Non-Vertebral Fractures	Number Other Non-Vertebral Fractures	Number Patients with Other Non-Vertebral Fractures
Placebo Daily	38	24	0	0	38	24	27	17	11	10
Risedronate Daily	42	29	0	0	42	29	28	18	14	12

Intervention	Participants (Number)
	At Least One New Fracture Vertebra	No New Fractured Vertebra
Placebo Daily	14	31
Risedronate Daily	20	62

Intervention	Participants (Number)
	Number Patients with New Vertebral Fractures	Number of New Vertebral Fractures	Number Patients New Fractures & Mild SQ Score	Number Patients New Fractures & Mod/Sev SQ Score
Placebo Daily	1	1	1	0
Risedronate Daily	10	13	10	1

Intervention	Participants (Number)
	No New Fractured Vertebra	One Fractured Vertebra	Two Fractured Vertebra	Three or more Fractured Vertebra
Placebo Daily	31	6	5	3
Risedronate Daily	62	10	7	3

Intervention	Probability of Fractures (Number)
	Number Patients All Fractures	All Fractures/Kaplan-Meier Cumulative Incidence	Number Patients Vertebral Fractures	Vertebral Fractures/Kaplan-Meier Cumulative Incid.	Number Patients Non-Vertebral Fractures	Non-Vertebral Fractures/Kaplan-Meier Cum. Incid.	Number Patients Long Bone Non-Vertebral Fractures	Long Bone Non-Vertebral Fractures/Kaplan-Meier Cum	Number Patients Other Non-Vertebral Fractures	Other Non-Vertebral Fractures/Kaplan-Meier Cum.
Placebo Daily	24	0.5043	0	0	24	0.5043	17	0.3618	10	0.204
Risedronate Daily	29	0.314	0	0	29	0.314	18	0.1954	12	0.1311

Intervention	nmol BCE/mmol creatinine (Median)
	at 24 week	baseline
Placebo Arm	62.95	48.08
Risedronate Arm	20.63	41.33

Intervention	percent change (Mean)
Parathyroid Hormone&Risedronate Placebo	0.85
Parathyroid Hormone&Risedronate	0.84
Parathyroid Hormone Placebo&Risedronate	0.91

Intervention	participants (Number)
	Responder to Treatment	Non-Responder to Treatment
Risedronate	220	116
Teriparatide	233	115

Intervention	participants (Number)
	Serious Adverse Events	Adverse Events
Risedronate	50	266
Teriparatide	39	269

Intervention	participants (Number)
	Day 0	Day 60	Day 120	Day 180	Day 240	Day 300	Day 360	Day 420	Day 480	Day 540	Day 600
Risedronate	0	74	145	181	193	206	209	220	220	220	220
Teriparatide	0	70	151	195	206	224	226	233	233	233	233

Intervention	participants (Number)
	Day 0	Day 30	Day 60	Day 90	Day 120	Day 150	Day 180	Day 210	Day 240	Day 270	Day 300
Risedronate	0	22	74	111	145	164	181	192	193	193	193
Teriparatide	0	26	70	110	151	175	195	206	206	206	206

Intervention	percentage of participants (Number)
	Any	Mild	Moderate	Severe
Ibandronate	46.1	41.3	32.3	15.6
Risedronate	56.5	49.1	36.0	12.4

Intervention	Percent of change (Mean)
	Lumbar Spine 6 Months	Right Hip 6 Months	Left Hip 6 Months
Actonel	-2.4	-7.6	-8.2
Placebo	-3.5	-11	-11

risedronic acid

Description

Cross-References

Synonyms (85)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Pathways (2)

Protein Targets (10)

Inhibition Measurements

Activation Measurements

Biological Processes (12)

Molecular Functions (9)

Ceullar Components (7)

Bioassays (221)

Research

Studies (1,256)

Market Indicators

Research Demand Index: 38.07

Study Types

Clinical Trials (95)

Trial Overview

Trial Outcomes

Change in Pain Interference Score

Change in Pain Severity Score

Number of Participants With a Disease Relapse During the Extended Observation Period

Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period

Number of Participants With a Partial Disease Relapse During the Extended Observation Period

Number of Patients Who Achieve Therapeutic Response at 6 Months.

Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28 Relative to Baseline

Relative Change in Serum Alkaline Phosphatase (SAP) in Units Per Liter (U/L) at Day 28

Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10

Relative Change in Urine Alpha C-telopeptide (α-CTx) in ug/mmol at Day 10

Time to First Therapeutic Response

Bone Mineral Density

Markers of Bone Metabolism

Number of Patients Who Had Therapeutic Response at 6 Months

Relative Change in Serum Alkaline Phosphatase in U/L at Day 28

Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10

Relative Change in Urine α-CTx in ug/mmol at Day 10

Time to First Therapeutic Response

Change in Pain Interference at Day 182

Change in Pain Severity at Day 182

Number of Participants With a Disease Relapse During the Extended Observation Period

Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period

Number of Participants With a Partial Disease Relapse During the Extended Observation Period

Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28

Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 24, ITT Population

Percent Change From Baseline in Lumbar Spine BMC (Bone Mineral Content) at Month 12, ITT Population

Lumbar Spine Z-score - Percent Change From Baseline to Month 36, ITT Population

Lumbar Spine Z-score - Percent Change From Baseline to Month 24, ITT Population

Lumbar Spine Z-score - Percent Change From Baseline to Month 12, ITT Population

Bone Age (Years), Change From Baseline to Month 36, ITT Population

Bone Age (Years), Change From Baseline to Month 24, ITT Population

Bone Age (Years), Change From Baseline to Month 12, ITT Population

Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population

Annualized Growth Velocity - Change From Baseline to Month 36, ITT Population

Annualized Growth Velocity - Change From Baseline to Month 12, ITT Population

Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 24, ITT Population

Number of Clinical Fractures, Month 12, ITT Population

New Morphometric Vertebral Fracture at Month 36, ITT Population

New Morphometric Vertebral Fracture at Month 12, ITT Population

Incidence New Vertebral Fractures by SQ Score, Patients Aged 10-15 Years, Month 12, ITT Population

Incidence New Vertebral Fractures by SQ (Semi-Quantitative) Score, Patients Aged 4-9 Years, Month 12, ITT Population

Categorization by Number of New Morphometric Vertebral Fracture at Month 36, ITT

Categorization by Number of New Morphometric Vertebral Fracture at Month 12, ITT

Wong-Baker FACES Pain Rating Scale - Change From Baseline to Month 12, ITT Population

Urine NTX/Cr - Percent Change From Baseline at Month 36, ITT Population

Urine NTX/Cr - Percent Change From Baseline at Month 24, ITT Population

Urine NTX/Cr - Percent Change From Baseline at Month 12, ITT Population

Total Body Z-score- Percent Change From Baseline to Month 36, ITT Population

Total Body Z-score- Percent Change From Baseline to Month 24, ITT Population

Total Body Z-score- Percent Change From Baseline to Month 12, ITT Population

Serum BAP - Percent Change From Baseline to Month 36, ITT Population

Serum BAP - Percent Change From Baseline to Month 24, ITT Population

Serum BAP - Percent Change From Baseline to Month 12, ITT Population

Intervention	percentage of change (Mean)
	Lumbar Spine 12 Months	Right Hip 12 Months	Left Hip 12 Months
Actonel	-0.6	-4.8	-4.1
Placebo	-5	-5.8	-7

Intervention	percentage change (Mean)
	CTX	P1NP
Active Medicine Group	-14.906	-46.863
Placebo Group	-4.077	-1.630

Intervention	percentage change (Mean)
	Total Hip BMD	Femoral Neck BMD
Active Medication Group	0.558	0.408
Placebo Group	-2.748	-2.137

Intervention	grams per square centimeter (g/cm^2) (Mean)
	Lumbar spine (n=38; n=39)	Hip (n=38; n=37)	Femoral neck (n=38; n=37)
Risedronate	0.037	0.007	-0.007
Teriparatide	0.068	0.014	0.014

Intervention	Newton per millimeter (N/mm) (Least Squares Mean)
	Axial compression stiffness at 6 months	Axial compression stiffness at 18 months	Axial compression strength at 6 months	Axial compression strength at 18 months
Risedronate	407.6	363.7	313.6	209.4
Teriparatide	890.7	1973.9	580.7	1287.5

Intervention	milligram per cubic centimeter (mg/cm^3) (Least Squares Mean)
	Integral BMD at 6 months	Integral BMD at 18 months	Trabecular BMD at 6 months	Trabecular BMD at 18 months
Risedronate	-1.91	0.68	-0.87	0.22
Teriparatide	-0.42	10.72	-0.70	9.53

Intervention	micrograms per deciliter (μg/dL) (Least Squares Mean)
	P1NP at 3 months	P1NP at 6 months	P1NP at 18 months
Risedronate	-16.09	-16.50	-15.58
Teriparatide	27.33	52.55	28.48

Intervention	nanograms per deciliter (ng/dL) (Least Squares Mean)
	β-CTx at 3 months	β-CTx at 6 months	β-CTx at 18 months
Risedronate	-0.15	-0.14	-0.11
Teriparatide	0.12	0.25	0.03

Intervention	participants (Number)
	Serious Adverse Events (SAEs)	Other Non-serious AEs	Fractures	Hypercalcemia
Risedronate	22	30	5	0
Teriparatide	13	22	0	0

Intervention	Newton/millimeter/radian (N/mm/rad) (Least Squares Mean)
	Anterior bending stiffness at 6 months	Anterior bending stiffness at 18 months	Axial torsion stiffness at 6 months	Axial torsion stiffness at 18 months	Anterior bending strength at 6 months	Anterior bending strength at 18 months	Axial torsion strength at 6 months	Axial torsion strength at 18 months
Risedronate	415705.0	233283.0	77830.7	56639.3	8827.2	4822.0	3664.0	2545.8
Teriparatide	664969.0	1209225.0	142902.9	279392.8	12490.9	26046.4	6127.7	14181.3